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ABSTRACT  
Placebo response, an apparent improvement in the clinical condition of patients 
randomly assigned to the placebo treatment, is a major issue in clinical trials on 
psychiatric and pain disorders. Properly addressing the placebo response is critical to an 
accurate assessment of the efficacy of a therapeutic agent. The Sequential Parallel 
Comparison Design (SPCD) is one approach for addressing the placebo response. A 
SPCD trial runs in two stages, re-randomizing placebo patients in the second stage. 
Analysis pools the data from both stages. In this thesis, we propose a Bayesian approach 
for analyzing SPCD data. Our primary proposed model overcomes some of the 
limitations of existing methods and offers greater flexibility in performing the analysis. 
We find that our model is either on par or, under certain conditions, better, in preserving 
the type I error and minimizing mean square error than existing methods. We further 
develop our model in two ways. First, through prior specification we provide three 
approaches to model the relationship between the treatment effects from the two stages, 
as opposed to arbitrarily specifying the relationship as was done in previous studies. 
Under proper specification these approaches have greater statistical power than the initial 
  vi 
analysis and give accurate estimates of this relationship. Second, we revise the model to 
treat the placebo response as a continuous rather than a binary characteristic. The binary 
classification, which groups patients into “placebo-responders” or “placebo non-
responders”, can lead to misclassification, which can adversely impact the estimate of the 
treatment effect. As an alternative, we propose to view the placebo response in each 
patient as an unknown continuous characteristic. This characteristic is estimated and then 
used to measure the contribution (or the weight) of each patient to the treatment effect. 
Building upon this idea, we propose two different models which weight the contribution 
of placebo patients to the estimated second stage treatment effect. We show that this 
method is more robust against the potential misclassification of responders than previous 
methods. We demonstrate our methodology using data from the ADAPT-A SPCD trial. 
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CHAPTER ONE: INTRODUCTION AND MOTIVATION 
1.1 Placebo Effect 
 The placebo effect, a beneficial response that cannot be attributed to the 
application of a treatment, is a major problem in clinical trials used for psychiatric 
diseases and pain related studies. This is especially serious in antidepressant clinical 
studies, where the placebo response rates (PboRR) are mostly between 30% to 40% [1]. 
A strong placebo response may impair the statistical assessment of the effectiveness of 
the active treatment. As a case in point, Iovieno and Papakostas [2] conducted a meta-
analysis based on 169 antidepressant monotherapy studies and 35 adjunctive 
polypharmacy studies to assess the relationship between the placebo response rate and the 
relative efficacy of active drug (antidepressant or adjunctive agent) versus placebo in 
clinical trials for major depressive disorders. For this, the investigators divided the trials 
into 4 groups based on the placebo response rate, namely PboRR <20%, 20% ≤ PboRR 
< 30%, 30% ≤ PboRR < 40%, and PboRR > 40%, and performed separate meta-
regressions and multiple regressions for each group. The results of their analysis are 
presented in Figure 1 and Figure 2. For antidepressant monotherapy studies, they showed 
that a higher placebo response rate correlated with a lower risk ratio of responding to 
antidepressant versus placebo, and this association was statistically significant (the 
PboRR increased from 16.2% to 46.2%, the risk ratio dropped from 2.62 to 1.25, and the 
p-value of association was <0.001). A similar trend was also observed in adjunctive trials. 
A higher placebo response rate correlated with a lower risk ratio of responding to the 
adjunctive drug versus placebo, and this association was again statistically significant 
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(the PboRR increased from 16.4% to 50.0%, the risk ratio dropped from 1.99 to 1.13, and 
the p-value of association was again <0.001).  
The high placebo response results in a high rate of failed trials, thus hampering 
drug development, and potentially preventing effective compounds from advancing to 
market. For instance, Shamsah et al. [1] showed that a third of the published 
antidepressant trials exhibited strong placebo response and failed to demonstrate 
statistical efficacy of the active treatment. This problem is likely more prevalent than it 
appears considering that a sizeable number of negative or failed trials remain 
unpublished.
 
Figure 1. The efficacy of antidepressants vs. placebo as a function of placebo response rates. 
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Figure 2. The efficacy of adjunctive drug vs. adjunctive placebo as a function of adjunctive placebo 
response rates. 
The driving forces behind placebo response can be very complicated, and several 
possible mechanisms have been proposed. These include: social and cultural factors, 
treatment situation factors, the physician-patient relationship, and biological factors [3]. 
To add to the complication, Enck et al. [4] conducted a literature review on the factors 
associated with placebo response. The author cited several meta-analyses evaluating the 
association of baseline symptom severity and improvement in placebo and active drug 
groups, and suggested that these two factors also contribute to the placebo response, e.g. 
lower symptom severity at study onset and improvement of symptoms during a drug-free 
run-in, exhibited different effects on the subjects in the drug-arm versus those in the 
placebo-arm of the clinical trials in the meta-analysis. Since these factors that contributed 
to the placebo response showed no relevance for the drug efficacy, the authors concluded 
that the placebo response in the drug-arm must be driven by different mechanisms.  
Not only can the factors behind placebo response have different effects on the 
placebo group and the drug group, studies have also shown that the placebo response can 
be seen not only as a characteristic that either present or absent in an individual but 
instead varies by the individual. For example, in studies on placebo response driven by 
underlying biological mechanisms, researchers have shown that placebo responsiveness 
is associated with the dopaminergic and opioid system, and high placebo response is 
observed with greater dopamine and opioid activity [5]. Since dopamine and opioid 
activities are present in and vary among individuals, this finding suggests that placebo 
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response is likewise a characteristic which is present in every individual albeit at different 
degrees. 
1.2 Sequential Parallel Comparison Design 
Placebo response is a critical problem in psychiatric clinical trials and it must be 
properly addressed in such trials. Directly addressing the mechanisms behind a placebo 
response is often difficult. Instead, new trial designs and new statistical analysis methods 
are needed to better address the problem of the placebo effect and to better demonstrate a 
treatment effect.  
Several experimental designs have been proposed for dealing with the placebo 
response problem. The first such design is the ‘placebo lead-in’ design. This design is a 
regular randomized double-blinded design with a placebo lead-in stage prior to 
randomization aimed at screening out patients who are likely to respond to placebo 
during the double-blind stage. The lead-in stage is typically a single-blinded period of 1 
or 2 weeks, during which the patients are unknowingly treated with placebo but their 
clinicians are aware of the placebo treatment. However, this design requires a longer trial 
duration, and later studies demonstrated that this design failed to minimize the placebo 
effect due to the clinician bias during the lead-in stage [6]. In 2003, Fava et al. proposed a 
new design, the sequential parallel comparison design (SPCD), which is believed to have 
more adequately addressed the placebo response problem [6] [7]. It is a design with two 
double-blind stages of equal duration for comparing the drug with a placebo on a measure 
of the disease. The flowchart of the SPCD design is shown in Figure 3. All patients have 
the outcome measured at baseline, and are then randomized to three groups PP (Placebo-
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Placebo), PD (Placebo-Drug), and DP (Drug-Placebo) in Stage I: the first two groups (PP 
and PD) of patients receive placebo and the third group (DP) of patients receives the 
study drug in Stage 1. After completing Stage I of the study, patients who do not respond 
to placebo in the first group (PP) continue on placebo in Stage II; patients who do not 
respond to placebo in the second group (PD) switch to the drug; patients who do not 
respond to the drug in the third group (DP) switch to the placebo in Stage II. Responders 
in those groups will either enter an open-label continuation therapy follow-up, or simply 
discontinue their double-blind treatment. The overall treatment effect is defined as a 
weighted average of the treatment effects from the two stages. Efficacy data from both 
stages, except the Stage II data from the DP group, will be used to estimate the weighted 
average treatment effect. The specified allocation ratio to drug and placebo in Stage II is 
generally unbalanced so that more patients will receive placebo. Afterwards, two small 
changes have been made to this design based on the suggestion by Tamura and Huang 
[8], and is shown in Figure 4. First, responders in Stage I will remain blinded throughout 
both stages of the trial. Second, non-responders to drug in Stage I will remain on drug 
instead of being switched to placebo in Stage II so that the efficacy and safety profiles of 
the drug over a longer period of time can be obtained. 
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Figure 3. The flowchart of SPCD design with three groups randomized initially.  
 
Figure 4. The flowchart of SPCD design with three groups randomized initially modified by Tamura 
and Huang. 
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However, a concern has been raised about this design. The treatment assignment 
in Stage II is pre-determined at the randomization of Stage I. When the numbers of 
placebo responders and/or the numbers of dropouts are different between the PP and PD 
groups in Stage I, the treatment allocation for Stage II may be highly unbalanced. This 
imbalance, if significant, may raise a concern with the validity of asymptotically normal 
test statistics and lead to insufficient power to detect a treatment difference in Stage II, 
particularly when the total number of evaluable patients in Stage II is small.  
To address this issue, this design has been further modified to a version with 
“placebo non-responder re-randomization”, as shown in Figure 5. All patients are 
randomized to either placebo or drug in the first stage. The typical composition of this 
randomization is 2:1 for placebo vs. drug. After Stage I, the patients who were assigned 
placebo are classified into placebo responders and placebo non-responders based on the 
Stage I outcome. In Stage II, the patients are re-randomized. Both the placebo responders 
and the placebo non-responders are re-randomized to either placebo or drug in a 1:1 ratio, 
while patients assigned to the active drug in Stage I are kept on drug in Stage II (note 
that, in the re-randomization process, some studies only re-randomize the placebo non-
responders to either placebo or drug but keep the placebo responders on placebo. In our 
research, we re-randomize both groups for ethical purposes.). As in a parallel design, the 
first stage is used to compare drug and placebo on all subjects, and to identify a cohort of 
placebo non-responders. The second stage is also used to compare the drug and the 
placebo, but usually focuses only on the group of placebo non-responders identified at the 
end of Stage I. The overall treatment effect is defined as a weighted average of the 
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treatment effects from the two stages. Where SPCD differs from previous designs is that 
all the patients recruited to the trial will contribute to the analysis. By re-randomizing the 
placebo non-responders, SPCD either increases the power of the study for a given sample 
size, or reduces the sample size needed to achieve the same power compared to other 
designs. In practice, SPCD can be conducted under either version--the version in Figure 4 
with single initial randomization or the version in Figure 5 with re-randomization. Both 
versions can be analyzed using the same statistical methods. In the rest of this thesis, we 
will use the version of SPCD illustrated in Figure 5 unless otherwise specified.   
 
Figure 5. The flowchart of SPCD design with re-randomization. 
 
1.3 Existing Methods for Analyzing SPCD Data 
Several statistical methods have been proposed to analyze data collected from a 
SPCD trial. The SUR (Seemly Unrelated Regression) method was proposed by Tamura 
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and Huang in 2007 [9]. In the SUR method, a liner regression using the baseline outcome 
value and treatment assignment as predictors is applied to predict the change from 
baseline in each stage. The Stage I analysis includes all subjects randomized to placebo 
or drug but the Stage II analysis only includes data from subjects randomized to placebo 
at Stage I who are non-responders. The SUR does not effectively utilize the data from the 
second stage of the trial, but opts to simply treat the outcomes of the patients who were 
either on active drug or placebo responders in Stage I as dropouts. The OLS (Ordinary 
Least Square) method proposed by Chen in 2011 [10] is very similar to the SUR method. 
However, the OLS makes a restrictive assumption that there is no correlation between the 
random errors from the two stages for subjects with data in both stages of the study. This 
assumption is unlikely to hold in practice since these data are measured on the same set 
of patients. Doros, in 2012 [11], proposed the Repeated Measures (RM) method. This is a 
mixed-effects model with repeated measures. The RM method uses all the outcome data 
collected in the trial and includes three liner regressions: one for Stage I, one for Stage II 
placebo non-responders, and one for Stage II placebo responders as well as those who are 
on drug in Stage I. This RM model was extended to the Weighted Propensity Score 
(WPS) and the Weighted K-mean Cluster (WKMC) methods by Rybin in 2014 in order 
to handle the potential misclassification of placebo responders and non-responders [12] 
[13]. However, all three of these methods are based on the repeated measure marginal 
model and thus suffer from the same shortcomings. First, they assume the variance-
covariance structures in Stage II are the same for all three groups (PR, PNR, DD), which 
is not very credible. Second, a model should condition on variables that are independent 
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from the outcome. However the repeated measure marginal model conditions on the 
individual placebo response status, which is the outcome derived from the Stage I. 
Moreover, the mixed-effect model uses the marginal likelihood representing the data. 
When observations are missing, the determination of the marginal likelihood is typically 
intractable [14].  
1.4 SPCD Study Example 
We will apply the proposed methods on data from a recent SPCD trial as an 
illustrative example throughout this dissertation. This trial is known as the ADAPT-A 
trial.  
The ADAPT-A trial, a multi-center, double-blind, placebo-controlled study of the 
efficacy of low-dose aripiprazole (2 mg/day) adjunctive to antidepressant therapy (ADT) 
in the treatment of major depressive disorder in patients with a history of inadequate 
response to prior ADT, was conducted using SPCD [15] with a single initial 
randomization (Figure 4). Patients were randomized to either aripiprazole-2 mg/day (n = 
54), placebo–placebo (n = 83), or placebo–aripiprazole-2 mg/day (n = 84) with a 2:3:3 
ratio. The patients were followed for 30 days in each stage (Stage I outcome measured at 
visit 3 and Stage II outcome measured at visit 6). The key secondary endpoint is the 
difference in the absolute change from the baseline in the Montgomery–Åsberg 
Depression Rating Scale (MADRS) score between aripiprazole-2 mg and placebo. The 
MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the 
severity of depressive episodes in patients with mood disorders. Each item yields a score 
of 0 to 60, and higher MADRS scores indicate more severe depression. The overall score 
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ranges from 0 to 60. Placebo nonresponse was defined at the end of Stage I as less than a 
50% decrease in MADRS total score from baseline and a MADRS score greater than 16. 
The outcomes are summarized in Table 1. 
 Measure Drug  Placebo 
Baseline N 
Mean±SD 
Range 
Median  
54 
30.69±4.02 
(23.00, 41.00) 
30.50 
167 
31.20±4.75 
(19.00, 45.00) 
31.00 
Change in Stage I N 
Mean±SD 
Range 
Median  
52 
-8.46±7.18  
(-28.00, 4.00) 
-8.00 
162 
-8.26±8.15 
(-35.00, 10.00) 
-6.50 
Change in Stage II N 
Mean±SD 
Range 
Median  
58 
-5.84±6.98  
(-27, 10) 
-4.00 
61 
-3.30±6.00 
(-23, 11) 
-3.00 
Table 1. Summary statistics of the baseline MADRS score and change for Stage I and Stage II 
(ADAPT-A trial). 
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Figure 6. The distribution of MADRS by visit for each group in ADAPT-A. Top: Placebo-Placebo 
group; middle: Placebo-Drug group; bottom: Drug-Drug group. 
  
 
Figure 7. The distribution of MADRS after Stage I for placebo subjects.  
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 Pearson Correlation Coefficients of MADRS 
score changes in Stage I and Stage II 
 
Placebo-Placebo 0.5027 
Placebo-Drug 0.1189 
Drug-Drug 0.0271 
Table 2. Pearson correlation coefficients of MADRS scores for each group in ADAPT-A trial. 
Descriptive statistics from the ADAPT-A are presented in Figure 6, Figure 7 and 
Table 2. Figure 6 shows the distributions of the baseline measurement of MADRS, the 
outcome from Stage I and the outcome from Stage II for each group (Top: Placebo-
Placebo group; middle: Placebo-Drug group; bottom: Drug-Drug group). We also look at 
the distribution of the MADRS of Stage I placebo subjects, and this is shown in Figure 7. 
The highly skewed distribution indicates that the distribution might represent a mixture 
distribution of responders and non-responders.  Table 2 shows that the Stage I outcome is 
positively correlated with the Stage II outcome for all three groups.   
1.5 Proposal in My Research 
The SPCD is a promising design for addressing the issue of high placebo response 
in clinical trials. SPCD substantially decreases the impact on trial outcomes of any 
placebo effect and will enable PPD (Pharmaceutical Product Development) clients to 
significantly reduce the time and cost of conducting their clinical trials. This design has 
been particularly effective in studying major depressive disorder (MDD), but is 
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applicable to clinical trials in many disease areas where outcomes can be impacted by 
placebo effects.  
However, further work is needed to develop methods to assess the treatment effect 
under SPCD.  In particular, the following are ideas to be addressed in this research.  
A new approach is needed to provide a better approximation of the likelihood 
representing the data, and this approach should allow the investigators to incorporate 
prior beliefs into analysis, should be based on more realistic assumptions, and offer better 
flexibility in the analysis. These improvements are very hard to implement under the 
frequentist framework used in previous studies. In this regard, the Bayesian framework is 
a better choice. In Chapter 2, we will propose a new Bayesian model to analyze SPCD 
data.  
The relationship between the treatment effects from the two stages is worth further 
investigation. In SPCD the overall treatment effect is measured as a weighted average of 
the treatment effects from the two stages, and these two effects are derived from data 
measured on the same patients. Therefore, these two effects are potentially related and 
the relationship warrants further investigation. Fava et al. [6] [16] provided evidence for 
this relationship, and concluded that because of the within-patient correlation, the 
treatment effect in Stage II is directly related to the treatment effect in Stage I. This 
relationship cannot be arbitrarily chosen when designing a trial. The current methods for 
analyzing SPCD data ignore this association, and therefore leave room for improvement. 
In 2010, Ivanova [17] claimed that in many SPCD applications with binary outcomes, in 
order to achieve optimal power, statistical tests should be developed based on the 
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observation that the estimated ratio of the rate difference in the second stage to the rate 
difference in the first stage is much greater than one. Her statement was based on the 
observed ratio of 8.8 from a recent study using SPCD in patients with major depressive 
disorder to compare the efficacy of low-dose aripiprazole with placebo [15]. However, no 
analytical method has been proposed to estimate this relationship and to account for the 
uncertainty of this assumed relationship. In Chapter 3, we will develop an analytical 
method to estimate this relationship and account for the uncertainty along with it 
properly.   
Also, when conducting a SPCD trial, as noted by Rybin et al. [12], the 
misclassification that occurs when dividing patients into “placebo responders” and 
“placebo non-responders” after Stage I is a major problem. By this binary classification 
criterion, the subjects receiving placebo in Stage I are defined as “non-responders” only if 
the improvement in their outcome measure is less than a fixed percentage compared to 
the baseline and greater than a pre-set threshold according to expert knowledge. For 
example, for psychology studies based on the MADRS score, investigators usually set the 
rule to classify subjects receiving placebo during Stage I into placebo responders and 
non-responders. A typical rule considers subjects that exhibit at least a 50% improvement 
from baseline with Stage I value greater than a pre-set threshold of 16 as placebo non-
responders. This formula of this placebo non-responder (NR) definition is:                                              
NR={
1,   ⅈ𝑓𝑧1 ≥
𝑧0
2
 𝑎𝑛𝑑 𝑧1 > 16 (𝑧1: 𝑆𝑡𝑎𝑔𝑒 𝐼 𝑜u𝑡𝑐𝑜𝑚𝑒; 𝑧0: 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑣𝑎𝑙𝑢𝑒)
0,    otherwⅈse
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  To illustrate how this criterion influences the effect estimation in SPCD, we apply 
the existing repeated measured model to the ADAPT-A trial data by varying the 
percentage of improvement from 50% to 40%. The estimation of the Stage II treatment 
effect is presented in Table 3. The 10% change in this criterion resulted in 1-unit change 
in magnitude and 1-unit change in standard error of the estimated treatment effect.    
Criterion Stage II (Stage I placebo non-responder) Treatment effect 
Mean (SE) 
50% improvement -2.75 (1.01) 
40% improvement -3.79 (0.96) 
Table 3. Effect of criterion change on SPCD Stage II treatment effect estimation. 
By current methods for SPCD, the placebo response is defined explicitly as the 
change in the outcome measure from baseline in subjects treated with placebo. But due to 
the biologic mechanisms mentioned in Section 1.1 and the distribution of the ADAPT-A 
outcome presented in Section 1.3, simply classifying subjects as placebo responders or 
placebo non-responders based on this change is susceptible to misclassification. Instead, 
viewing the “placebo response” as a continuous measure that is present to some degree in 
every patient, may reduce such misclassification. In reality, the placebo non-response 
characteristic is unknown and needs to be estimated. This characteristic can be used to 
measure the contribution (weight) of each patient to the estimate for Stage II. For these 
reasons, in Chapter 4 we consider Bayesian weighted methods. We will propose two 
Bayesian models that differ in how they incorporate the “weight”. The potential feedback 
problem also needs to be taken into consideration [18]. Here “feedback” is taken to be the 
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phenomenon that the “weight” for Stage II is estimated in the model using Stage I data. 
But, the data from Stage II can also influence estimation of the weight. Proper technique 
is needed to handle the feedback problem. 
This dissertation includes three projects. The first project proposes a new 
Bayesian full probability model for analyzing SPCD data. The second project proposes 
three methods to develop and quantify the relationship between the estimates from the 
two stages of a SPCD trial based on the Bayesian full probability model proposed in the 
first project. The third project aims to address placebo response misclassification under 
the Bayesian framework and offers proper techniques to deal with potential feedback. 
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CHAPTER TWO: A FULL PROBABILITY JOINT MODEL FOR THE 
ANALYSIS OF SPCD DATA 
2.1 Introduction 
As mentioned in Chapter 1, though several statistical methods have been proposed 
to analyze SPCD data, all have their shortcomings. The SUR does not effectively utilize 
data from the second stage of the trial, simply treating the outcomes of the patients who 
were either on active drug or placebo responders in Stage I as dropouts [8]. The OLS 
makes an unrealistic assumption that there is no correlation between the drug effect 
estimates from the two stages, which does not hold in practice since the two estimates are 
derived from data measured on the same patients [10].  The three methods (RM, WPS, 
WKMC) based on the repeated measure marginal model all assume the variance-
covariance structure in Stage II is identical for all three groups (PD, PP, DD). This is 
generally not credible [11] [12] [13]. Moreover, the model should condition on the 
variables that are independent from the outcome. However, the repeated measure 
marginal model conditions on the individual placebo response status, which is the 
outcome derived from the Stage I. Lastly, when observations are missing, the 
determination of the marginal likelihood is typically intractable [14] [19]. New 
approaches are needed to overcome the limitations of the existing methods, thus 
providing a better way to analysis SPCD data. 
In this chapter, we propose a Bayesian joint full probability model to analyze 
SPCD data.  The methodology for the proposed Bayesian model, including the model 
specification and prior specification, is presented. Our proposed method has several 
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advantages over the existing methods.  Firstly, our Bayesian model is a probability model 
providing a better approximation of the likelihood of the data, in the sense that it assumes 
different mean structures and variance-covariance structures for each group and can 
estimate the treatment effects from both stages as well as the covariance structures 
simultaneously based on posterior distribution, whereas the previous models have no 
ability to estimate the variance structure differently for each group. Secondly, by 
incorporating prior information into the model, the Bayesian approach can leverage 
existing scientific knowledge and available evidence independent of the study at hand. 
This chapter is organized as follows. In section 2.2, the methodology and the 
models for the proposed methods are presented. In section 2.3, an extensive simulation 
study is conducted to compare the performance of our methods to existing methods. In 
section 2.4, we use the proposed models to analyze ADAPT-A trial data, and the results 
are compared to those obtained using existing methods. The conclusion and discussion 
make up the last section 2.5. In this paper, unless otherwise stated, we use bolded letters 
to denote sets of random variables. For example, 𝜶 = {α1, α2} etc. 
2.2 Methodology 
2.2.1 SPCD Design and Parametrization 
The SPCD is designed to evaluate a new treatment vs. a placebo in the presence 
of placebo effects. The diagram in Figure 8 shows the parametrization of the design. The 
design has two stages of equal duration to compare the active drug (D) and placebo (P) on 
a measure of the disease (outcome, where lower values represent less disease). The study 
progress goes from left to right, with dashed lines for drug (D) and solid lines for placebo 
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(P). All patients have the outcome z0 measured at baseline, and are then randomized to 
either placebo or drug in the first stage. The typical composition of this randomization is 
2:1 for placebo vs. drug. After Stage I, the mean change in the outcome measure is δ0 for 
subjects on placebo, and (δ0 + δ1) for subjects on drug. Moreover, after Stage I, the 
patients who were assigned placebo are identified and classified into placebo responders 
(P+) and placebo non-responders (P−) based on the outcome z1 . Note that δ0 is actually 
a combined effect of δ01 and δ02, which are the changes in the outcome measures in 
placebo non-responders and placebo responders respectively. In Stage II, the participants 
are re-randomized.  Several different Stage II treatment allocation plans have been 
proposed for SPCD trials. We apply the idea of enrichment for ethical purposes. That is 
to say, in Stage II, both the placebo responders and the placebo non-responders are re-
randomized to either placebo or drug in a 1:1 ratio, while patients assigned to the active 
drug in Stage I are kept on drug in Stage II. Outcome z2 is measured again at the end of 
Stage II. Among the placebo non-responders, δ2 is the mean change for patients on 
placebo, whereas (δ2 + δ31) is the mean change for patients on drug; among the placebo 
responders, δ4 is the mean change for patients on placebo, whereas (δ4 + δ32) is the 
mean change for patients on the drug.  The parameters δ1 and δ31 are the magnitude of 
the treatment effects in Stage I and Stage II, respectively. The overall treatment effect is 
defined as a weighted average of the two stages: δ =  ν ∗ δ1 + (1 − ν) ∗ δ31, where ν can 
be chosen to optimize the power for a given treatment allocation. [11]  
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Figure 8. SPCD design parameterization diagram. 
 
2.2.2 Proposed Model 
The data from a SPCD consist of three continuous measures gathered from each 
subject: the baseline value z0, the outcome z1 from Stage I, and the outcome z2 from 
Stage II. Since we are interested in the changes in outcome, we use y1 = z1 − z0 and y2 = 
z2 − z1 as the responses in the model. We also have two variables T1 and T2 representing 
the treatment assignment for each subject in Stage I and Stage II respectively, taking on 
the value 1 for drug and 0 for placebo. We define placebo non-responders as the subjects 
for whom the outcome at the end of Stage I is both at least half of the baseline value and 
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above a certain fixed non-response threshold. We construct a joint linear regression 
model assuming normality of the errors of the outcomes.  
The Bayesian formulation for this model is:   
  Stage I       
        Likelihood       y1i ~ N(μ1i, σ1
2) 
        Model             μ1i = α1 + α2 ∗ z0i
∗ + δ1 ∗ T1i 
Stage II        
         Likelihood       y2i ~ N(μ2i, σ2,Ri
2 ) 
         Model         μ2i =  βRi,1 + βRi,2 ∗ z1i
∗ + δRi,1 ∗ T2i,  wⅈth ⅈ = 1: 𝑛, and Ri = 1, 2 or 3 
where Ri is the ‘treatment-response combination status’ in Stage II for subject i, with 
arbitrarily assigned value 1, 2, and 3, corresponding to the drug-drug group, the placebo-
responder group, and the placebo-non-responder group in Stage II respectively. z0i
∗  and 
z1i
∗  are the centered baseline values in Stage I and Stage II. The total number of subjects 
is designated by n.  
In Stage I, the outcome is related to the baseline and Stage I treatment assignment 
for the subjects on placebo and on drug in the study. In Stage II, for the Stage I placebo 
non-responders, the outcome at the end of Stage II is related to the Stage II baseline and 
treatment assignment for placebo non-responders. On the other hand, for the Stage I 
placebo responders, the outcome at the end of Stage II is related to the Stage II baseline 
and treatment assignment for placebo responders. Finally, for subjects randomized to 
drug in Stage I, the outcome at the end of Stage II is related solely to the Stage II baseline 
value since there is no treatment randomization in Stage II. This way, we assume 
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different mean structures and different variance structures for Stage II outcome for the 
model in placebo responders, placebo non-responders, and subjects on active treatment in 
phase I. Treatment effects for each group are summarized in Table 4.  
 Mean Structure Variance 
Structure  
Stage I D α1 + α2 ∗ z0i
∗ + δ1 σ1
2 
Stage I P α1 + α2 ∗ z0i
∗  σ1
2 
Stage II P Non- Responder taking D     β31 +  β32 ∗ z1i
∗ + δ31 σ2,3
2  
Stage II P Non-Responder taking P β31 + β32 ∗ z1i
∗  σ2,3
2  
Stage II P Responder taking D β21 + β22 ∗ z1i
∗ +  δ21 σ2,2
2  
Stage II P Responder taking P β21 + β22 ∗ z1i
∗  σ2,2
2  
Stage II D kept on D β11 + β12 ∗ z1i
∗ + δ11 σ2,1
2  
Table 4. Treatment effects summarized by group under proposed model. 
This way, our proposed model has several advantages over the existing methods. 
Compared with SUR, we utilize all the trial data; compared with OLS, we assume 
correlation between stages; compared with RM, WPS and WKMC, we give a different 
variance-covariance structure to each group in Stage II and also provide a more refined 
likelihood for representing the data.  
2.2.3 Prior Specification 
One of the most important differences between the Bayesian paradigm and the 
frequentist paradigm is that the Bayesian approach allows for the incorporation of prior 
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beliefs into the model. The prior distribution captures the external knowledge of the 
experiment, allowing us to quantify the uncertainty of the unknown parameters. Bayesian 
inference is based on a combination of prior and current information (the likelihood) 
which is reflected in the posterior distribution. Our model is initially specified with non-
informative independent priors. We will discuss other options for priors in the sensitivity 
analysis. Note that, even in the absence of strong prior information, prior specification 
should be done at the appropriate scale based on general and well known biological facts. 
In our case, the priors on treatment effect should be chosen to represent the possible 
range of MADRS.  
In our model, the independent priors are assigned to each parameter as α1 ~ 𝜋1
𝛼 ,
α2 ~𝜋2
𝛼 ,  β11~𝜋11
𝛽
 , β12~ 𝜋12
𝛽
, β21~𝜋21
𝛽
, β22~𝜋22
𝛽
, β31~ 𝜋31
𝛽
, β32~ 𝜋32
𝛽
, δ1 ~ 𝜋1
𝛿 ,  
 δ11~𝜋11
𝛿 , δ21~𝜋21
𝛿 , δ31~ 𝜋31
𝛿 , 
1
𝜎1
2  ~ 𝜋1
𝜎 ,
1
𝜎21
2  ~ 𝜋21
𝜎 ,
1
𝜎22
2  ~ 𝜋22
𝜎 , 
1
𝜎23
2  ~ 𝜋23
𝜎 . 
Here the 𝜋′𝑠 stand for general distributions. The joint full probability model is 
𝑓(𝜶, 𝜷, 𝜹, 𝚺 |𝑦1, 𝑦2, 𝑇1, 𝑇2, 𝑅) ∝ 𝑓( 𝑦1, 𝑦2, 𝑇1, 𝑇2, 𝑅|𝜶, 𝜷, 𝜹, 𝚺) ∗ π(𝛂) ∗ 𝜋(𝛃) ∗ π(𝛅) ∗
π(𝚺). 
Bayesian Hypothesis Testing:    
A Bayesian approach to a frequentist test for H0: δ ≥ 0 vs H1: δ < 0 is to directly 
calculate the probability of H0 based on the posterior distribution of δ. In a one-sided test, 
numerically the posterior probability can be comparable with the p − value from the 
corresponding frequentist test. The posterior probability derived this way is considered as 
the Type I error rate and is often set to be significant at pre-specified level.  
 Pr(H0|𝑑𝑎𝑡𝑎) = Pr(𝛿 ≥ 0|𝑑𝑎𝑡𝑎) = 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
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Implementation:  
                  The Markov Chain Monte Carlo (MCMC) algorithm is implemented using the 
OpenBUGS software to generate the posterior distribution of the unknown quantities in 
the statistical model. With sufficiently many MCMC samples, this algorithm can generate 
an accurate representation of the posterior distribution. The summary diagnostic statistics 
are computed from these draws.  
2.2.4 Simulation Study to Evaluate the Bayesian Full Probability Model 
We performed a simulation study to assess the operating characteristics of the 
proposed Bayesian method with non-informative independent priors, as well as to 
compare the Bayesian method to previous known methods. In generating data, the 
parameter values were chosen based on the results of a recent clinical trial for a 
psychiatric disorder in which the MADRS (Montgomery–Åsberg Depression Rating 
Scale) was used as an outcome [15]. To establish a baseline, we initially specify the 
parameters. The mean and standard deviation (SD) of the outcome at baseline were set to 
31 and 5, respectively. The SD of the change from baseline to the end of Stage I and the 
SD of the change from baseline to the end of Stage II were both set to 7. The correlation 
between the baseline and the changes in both Stage I and Stage II was set to 0.1. “Non-
responders” were defined as subjects for whom the outcome at the end of Stage I is both 
at least half the baseline value and above the fixed threshold of 16 (16 is a common 
choice in categorizing the MADRS score scale). The proportion of non-responding 
placebo subjects was set to be approximately 75% of the subjects on placebo. The mean 
change in Stage II among subjects on drug in Stage I was assumed to be τ=60% smaller 
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than the corresponding mean change in Stage I. The investigations in Doros et al. [11] 
showed that the performance characteristics of the method are not sensitive to the choice 
of τ. We set a 2:1 randomization in favor of placebo in Stage I, and a 1:1 re-
randomization in Stage II among subjects who were on placebo in Stage I. The following 
total sample sizes were considered: 75, 90, 120, 150 and 300 subjects. The inter-stage 
correlations between the changes in the outcome during Stage I and the changes in the 
outcome during Stage II were expressed as r, and set to be the same for all treatment 
arms, and they range from −0.4 to 0.4 in 0.1 increments. Treatment effects for power 
calculations were built in by appropriate selection of δ1, δ31and δ32. For power 
calculation, treatment effects δ1 and δ31 are set to be the same and are equal to 0.3 SD 
and 0.5 SD. We also relate δ32 = h*δ31, indicating a smaller effect in placebo-responder 
group by setting h =0.8. The values of δ1,δ31, and δ32were set to 0 for assessing the Type 
I error. In the literature, the SPCD effect weight ν is chosen typically to be a value larger 
or equal to 0.5 and often 0.8 and we picked 0.64 for our simulation. By fixing the 
proportion of non-responding placebo subjects pNR, the parameters δ0, δ01, and δ02 can 
be calculated using Monte Carlo methods and the formulas developed in [11]. The data 
were generated from a multivariate normal distribution in each arm. 
In analyzing simulated data, non-informative independent priors are specified for 
the unknown parameters in the Bayesian Full Probability model as follows: 
α1, α2, β11, β12, β21, β22, β31, β32, δ1, δ11, δ21, δ31~ 𝑁(0, 50 
2), 
1
𝜎1
2 ,
1
𝜎21
2 ,
1
𝜎22
2 ,
1
𝜎23
2 ~ 𝐺(10
−3, 10−3). Here 𝑁(0, 50 
2) stands for the normal distribution with 
mean of 0 and standard deviation of 50. When little is known about the parameter, it is 
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common to set the location parameter to zero and the scale to some large value; in the 
context of our simulation 50 is a large value. Our estimation and the test are not very 
sensitive to the choice of the scale. The 𝐺(10−3, 10−3) stands for the gamma distribution 
with shape parameter of 10−3 and rate parameter of 10−3.  
For each scenario, we generated 10,000 datasets which were analyzed using the 
proposed Bayesian full probability method as well as the existing OLS, SUR, RM, 
WKMC and PS methods. The model in the proposed Bayesian Full Probability method 
was fitted in OpenBUGS using a MCMC algorithm, and was run for 10,000 iterations 
including 1,000 burn-in samples, with one chain initialized to starting values. All results 
reported here converged unless stated otherwise. 
We estimated the Type I error, the mean squared error (MSE) of the estimated 
parameters, and the power of the proposed method, and compare with the existing 
methods. All simulations were performed in R and OpenBugs on a Linux cluster. The 
scripts are available in the Appendix. 
2.3 Results 
We compare the Type I error, the MSE, and the power between our proposed 
Bayesian full probability method and existing methods under many scenarios based on 
different parameter combinations. The results are presented in Figure 9 to Figure 12.  
 
TYPE I ERROR: With 10,000 independent samples, differences in observed Type I error 
of 0.005 would be significant. For small to medium-size samples, the proposed procedure 
performed on par with the OLS, SUR and RM models, having a comparable or strictly 
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lower Type I error. On the other hand, in all the scenarios, our proposed method 
performed better than the KM and PS methods, both of which exhibit slightly inflated 
Type I error. Also, note that SUR and OLS performed similarly in all configurations, 
which is expected given they both ignore the data from the placebo responders and those 
who are on drug in Stage I. For large-size samples, all the methods performed similarly. 
The Type I error is preserved for the proposed Bayesian method in all combinations of 
sample sizes and correlation structures. (Figure 9) 
 
Figure 9. Type I error by correlation structure. SUR, seemingly unrelated regression; OLS, ordinary 
least squares; PM, repeated measure; PS, propensity score; WKMC1.5, weighted k means cluster; 
Bayesian, proposed method; r, the correlations between the changes in the outcome during Stage I 
and the changes in the outcome during Stage II. 
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MSE: First we note that the MSE for all methods decreased as the sample size increased. 
Under all the sample sizes and correlation combinations, our proposed method exhibited 
a slightly larger MSE relative to other methods. This is not surprising given the Bayesian 
method inherently incorporates more variability, and is capable of estimating more 
parameters than frequentist methods, thus resulting in a larger MSE. The RM, OLS, SUR 
and KM methods showed very comparable MSE while PS had the smallest MSE under 
all situations. We also note that the MSE of all methods exhibited quadratic dependency 
on the correlation, reaching a maximum when the correlation is 0. This is also expected, 
as we know that when the correlation is nonzero, the standard error of the weighted 
average from Stage I and Stage II can be reduced, leading to a more precise estimate. 
(Figure 10) 
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Figure 10. MSE by correlation structure. SUR, seemingly unrelated regression; OLS, ordinary least 
squares; PM, repeated measure; PS, propensity score; WKMC1.5, weighted k means cluster; 
Bayesian, proposed method; r, the correlations between the changes in the outcome during Stage I 
and the changes in the outcome during Stage II. 
 
POWER: With 10,000 independent samples, differences in estimated power of 0.01 
would be needed for significance with power around 70%. The power assessment shows 
that with comparatively high effect size (0.5 SD), all the methods performed similarly 
except for PS, which had a slightly higher power for almost all correlations. In this 
situation, under all the combinations of correlation and sample size, all the methods were 
successfully powered at 70% or higher (Figure 11). Power increased as sample size 
increased under any correlation structure. For the lower power situations (0.3 SD), our 
proposed method still has comparable power relative to the existing methods. For the 
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small sample size, all methods were under powered. But as the sample size increased to 
300, all the methods were powered at least 85%. (Figure 12) 
  
Figure 11. Power by correlation structure, for effect sizes of 0.5 SD. SUR, seemingly unrelated 
regression; OLS, ordinary least squares; PM, repeated measure; PS, propensity score; WKMC1.5, k 
means cluster; Bayesian, proposed method. 
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Figure 12. Power by correlation structure, for effect sizes of 0.3 SD. SUR, seemingly unrelated 
regression; OLS, ordinary least squares; PM, repeated measure; PS, propensity score; WKMC1.5, k 
means cluster; Bayesian, proposed method. 
2.4 ADAPT-A Trial Example 
The proposed model was applied to ADAPT-A trial data with the non-informative 
priors, and compared to the result obtained from previous methods. The results are 
summarized in Table 5. Under all methods, there is no significant difference in the 
combined adjusted mean outcome. For the Bayesian method, the effect as shown are 
estimated with 95% credible interval to be -1.107 (-2.927, 0.669). Comparing to the 
existing methods which utilized all the data, our proposed method gave a larger estimate 
in Stage I, and a larger estimate than RM and PS in Stage II. Overall, the results are all 
similar in terms of the test statistic and its significance. History, autocorrelation, and 
density plots, presented in Figure 13, are used to assess the convergence of the sampler. 
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Visual inspection of the time series plot produced by “history” suggests that the Markov 
chains have converged. The histogram of the posterior samples of the mean looks 
symmetrical for all the treatment effects. The autocorrelation also seems to have 
disappeared after first 10 lags, proving efficient inferences for our model. Though the 
autocorrelation for δ31 is higher than δ1 and δ, it can be reduced by thinning the sample 
by 2. 
Method Stage I 
Estimate 
Stage II 
Estimate 
 
Overall 
Estimate 
SD of 
overall 
estimate 
Test 
statistics 
P-value 
Proposed 
Bayesian 
-0.295 -2.551 -1.107 0.918  0.111* 
RM -0.268 -2.491 -1.068 0.912 -1.170 0.121 
OLS -0.289 -2.524 -1.094 0.915 -1.196 0.116 
SUR -0.286 -2.553 -1.102 1.735 -1.204 0.228 
PS -0.293 -2.397 -1.051 0.845 -1.240 0.107 
KMC1.5 -0.288 -2.626 -0.872 0.923 -0.950 0.172 
Table 5. ADAPT-A estimates of treatment effects comparison based on the six methods using 
ADAPT real data 
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Figure 13. History, Density and Auto Correlation of estimates, treatment effect in Stage I, II and 
overall. 
It should also be noted that the real ADAPT trial data include missing data on 
both outcome responses and covariates. For the missing response, OpenBUGS will 
automatically generate values from its posterior predictive distribution. For the missing 
covariates, OpenBUGS has no automatic way of dealing with them. The missing 
covariates must be given a prior distribution to fully specify the probability model. The 
easiest way is to give each covariate a normal prior with unknown mean and variance, 
and then the observed covariates can provide information about these prior parameters. 
The missing covariate is then imputed, automatically taking into account the prior 
distribution and the observed response. The OpenBUGS code for doing this is available 
in the Appendix.  
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2.5 Conclusions 
We proposed a new Bayesian method for analyzing SPCD trial data with 
continuous outcomes. The method provides a direct full probability model that can reflect 
the true likelihood of the data and allow us to estimate the treatment effects in both stages 
simultaneously. Our proposed method also has the flexibility to incorporate prior 
knowledge, which will benefit the study in later chapters. The simulation study showed 
that, in most common situations, our method displayed similar or improved performance 
to previous existing approaches. For small to medium sample sizes, the method proposed 
here gave better control of Type I error. Our proposed method generated a slightly larger 
MSE, due to the uncertainty assigned to the model parameters in Bayesian methods that 
add variability to the estimates of the main parameters.  
Our proposed model is able to handle missing response and missing covariates. The 
ADAPT-A trial data used in an application of the proposed method, has missing response 
and missing covariate. For missing covariates, we gave a prior distribution to fully 
specify the probability model. For missing response, OPENBUGS imputed values from 
the posterior predictive distribution under the assumption that the data are missing 
completely (or mostly) at random. Under this assumption, the probability of data being 
missing does not depend on observed or unobserved data. However, if the missing 
response mechanism is informative, we will need to model it, and we will often need 
informative priors to do this since no information exists in the data themselves. 
Extensions can also be made in the future to explicitly model any known missing data 
mechanisms. To summarize, we believe that our approach offers a competitive alternative 
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for the analysis of data from SPCD trials. The OpenBUGS and R scripts used in 
conducting this research are available in Appendix.  
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CHAPTER THREE: ESTIMATING THE RELATIONSHIP OF TREATMENT 
EFFECTS FROM TWO STAGES THROUGH PRIOR SPECIFICATION  
3.1 Introduction 
In SPCD, the relationship between the treatment effects in Stage I and Stage II 
placebo non-responders can be important and worth investigation. As we described in 
Chapter 2, the overall treatment effect is calculated as a weighted average of the 
individual treatment effects from the two stages-Stage I and Stage II placebo non-
responders, and these two effects are derived from data measured on the same patients. 
Therefore, clinically and statistically, these two effects are potentially related and this 
relationship warrants further investigation. In 2003, Fava M. et al [6] examined this 
relationship. They studied how the within-patient correlation together with the Stage I 
treatment effect influenced the Stage II treatment effect in SPCD. They found that, 
because of the within-patient correlation, the treatment effect in Stage II was directly 
related to the treatment effect in Stage I. Many of the existing methods for analyzing 
SPCD data ignore this association, and therefore there is room for improvement over 
these methods. In 2010, Ivanova [17] claimed that in many SPCD applications with 
binary outcomes, in order to have optimal power, the statistical tests should be developed 
based on the observation that the estimated ratio of the rate difference in the second stage 
to the rate difference in the first stage is much larger than one. More precisely, her 
statement was based on the observed ratio of 8.8 from a recent study using the SPCD in 
patients with major depressive disorder comparing the efficacy of low-dose aripiprazole 
with placebo [6]. However, this relationship cannot be arbitrarily assumed when 
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designing a trial. No analytical method has been proposed to estimate this relationship 
and to account for the uncertainty in this assumed relationship. 
Based on the Bayesian full probability model proposed in Chapter 2, we propose to 
use informative priors to provide a model to inform this relationship. More precisely, we 
choose informative priors that reflect our knowledge about the existence and nature of the 
relationship between the treatment effects from Stage I and Stage II placebo non-
responders in an SPCD. We model the two priors jointly to capture this relationship. 
Moreover, the model provided by joint priors can be chosen to further reflect the belief 
that the Stage II treatment effect is greater than the Stage I treatment effect. This contrasts 
with the proposal in Chapter 2 where independent priors are assigned to the treatment 
effect in each stage. One significant benefit of this approach is that by incorporating joint 
priors into the model, we have a way to verify and estimate the relationship between the 
treatment effects from the two stages of the study. While this relationship has been 
discussed and arbitrarily assumed in previous methods for analyzing SPCD data, no 
method for estimating it has been proposed until now. Furthermore, we propose different 
joint priors to assess this relationship, and inform us on which choice of priors captures 
features of the real data better. 
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3.2 Methodology  
3.2.1 SPCD Parameterization  
The parameterization of SPCD in this chapter is the same as in Chapter 2. The 
parameters δ1 and δ31 are the magnitude of the treatment effects in Stage I and Stage II 
placebo non-responders, respectively. The overall treatment effect is defined as a 
weighted average of the two stages: δ =  ν ∗ δ1 + (1 − ν) ∗ δ31, where ν can be chosen 
to optimize the power for a given treatment allocation [11].  
3.2.2 Proposed Method  
The proposed method to quantify the relationship between δ1 and δ31 is based on 
the Bayesian full probability model proposed in Chapter 2.  
δ1 and δ31 are the model-based treatment effect estimates from Stage I and Stage 
II Placebo non-responders respectively. In each case, the parameter estimates are taken to 
be the posterior mean. The estimated contrast of interest is δ = ν ∗ δ1 + (1 − ν) ∗ δ31, 
which represents the weighted average treatment effect. 
Now, unlike the procedure in Chapter 2 where the independent non-informative 
priors are assigned on δ1 and δ31, in order to further investigate the relationship between 
δ1 and δ31 , we assign informative priors for them.  
By the evidence provided by Fava et al. [6], we believe δ1 and δ31 are related, 
and δ31 is greater than δ1. This belief leads to a joint modeling of the priors on δ31 and 
δ1. To reflect the relationship between δ1 and δ31, we can either model the difference 
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between them or model the ratio of them. In all we will investigate three different joint 
priors in this chapter. 
 In the first prior, we model the difference to reflect the relationship. Let 
δ1 and δ31 be the treatment effects in Stage I and Stage II respectively. With this prior, 
we assume a bigger effect in Stage II and that the difference follows an exponential 
distribution, explicated as follows: 
δ1 ~ π1
δ 
δ31 = δ1 + θ , θ~ exp(λ),  wⅈth expected p(θ > cp) = 0.9, 
where cp is chosen so that the probability of observing a difference greater than cp is 0.9.  
 
With the second prior, we model the ratio of δ31to δ1 to reflect the relationship. 
We represent the ratio of two stages by κ + θ with a fixed mean κ and an additive 
impulse random variable θ, explicated as below:   
δ1 ~ π1
δ 
δ31
δ1
= (κ + θ) , θ~𝜋𝜃, with κ varies from 0.8 to 2.2. 
 
With the third prior, we still model the ratio to reflect the relationship. But instead 
of assuming a fixed mean for the ratio, we propose to model the relationship between 
δ1 and δ31 by a random ratio κ with a prior distribution π
κ. We believe this setting is 
superior to the first two settings because not only can it incorporate the knowledge that 
δ31 is greater than δ1, it can also provide a more accurate estimation of this relationship 
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since the effects are expected to be proportional to each other based on previous studies. 
This setting is explicated as follow: 
δ1 ~ π1
δ 
δ31
δ1
= κ, κ~πκ, wⅈth expected p(κ > 1) = 0.8. 
3.2.3 Simulation Study 
We conducted a simulation study to measure the robustness of results to the 
selection of prior distributions. We then examine our estimation of the relationship 
between the effects from the two stages. We study the operating characteristics under the 
joint priors by comparing the results against those obtained by using independent priors 
in Chapter 2.  
When generating the data, we use identical settings as those from Section 2.2.4 in 
Chapter 2 in order to make a proper comparison. Recall that, under the alternative 
hypothesis, treatment effects δ1 and δ31 are generated to be the same and both are equal 
to 3.5. For each scenario, we generated 10,000 datasets which were analyzed using the 
joint informative priors as well as the independent non-informative priors.  
For the prior specification, we also keep all the priors the same as the priors in 
Section 2.2.3 in Chapter 2, except for the prior on δ31. Instead of using the independent 
non-informative prior 𝑁(0, 50 
2) on δ31, we specify the joint informative priors on δ31. 
The joint priors under different assumptions are presented in Table 6, Table 7 , and Table 
8.  
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 𝜆 cp Stage I prior Stage II prior 
Prior 1.1 1 0.1 δ1 ~𝑁(0, 50
2) δ31 = δ1 + θ , θ~ exp(1)  
Prior 1.2 0.2 0.5 δ1 ~𝑁(0, 50
2) δ31 = δ1 + θ , θ~ exp(0.2)  
Prior 1.3 0.13 0.8 δ1 ~𝑁(0, 50
2) δ31 = δ1 + θ , θ~ exp(0.13)  
Prior 1.4 0.1 1 δ1 ~𝑁(0, 50
2) δ31 = δ1 + θ , θ~ exp(0.1)  
Table 6. Joint informative prior I: relationship in the form of a random difference 𝜽, that 
is exponential-distributed with the rate 𝝀 specified. 
 
Table 7. Joint informative prior II: relationship in the form a ratio 𝜿 + 𝜽 with a fixed mean of 𝜿 and 
random variability 𝜽, that is normal-distributed with mean and variance specified. 
 
 
 
 
 
 
 
 Fixed 𝜅 Stage I prior Stage II prior 
Prior 2.1 2.2 δ1 ~𝑁(0, 50
2) δ31 = 2.2 ∗ δ1 + δ1 ∗ θ , θ~N(0, 0.1) 
Prior 2.2 2 δ1 ~𝑁(0, 50
2) δ31 = 2 ∗ δ1 + δ1 ∗ θ , θ~N(0, 0.1) 
Prior 2.3 1.5 δ1 ~𝑁(0, 50
2) δ31 = 1.5 ∗ δ1 + δ1 ∗ θ , θ~N(0, 0.1) 
Prior 2.4 1 δ1 ~𝑁(0, 50
2) δ31 = 1 ∗ δ1 + δ1 ∗ θ , θ~N(0, 0.1) 
Prior 2.5 0.8 δ1 ~𝑁(0, 50
2) δ31 = 0.8 ∗ δ1 + δ1 ∗ θ , θ~N(0, 0.1) 
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 Shape Scale Stage I prior Stage II prior 
Prior 3.1 0.5 33 δ1 ~𝑁(0, 50
2)   δ31 =  κ ∗ δ1 , κ~G (0.5, 33) 
Prior 3.2 1 4.50 δ1 ~𝑁(0, 50
2) δ31 =  κ ∗ δ1 , κ~G (1, 4.5) 
Prior 3.3 2 1.22 δ1 ~𝑁(0, 50
2)  δ31 =  κ ∗ δ1 , κ~G (2, 1.22) 
Prior 3.4 3 0.66 δ1 ~𝑁(0, 50
2)  δ31 =  κ ∗ δ1 , κ~G (3, 0.66) 
Prior 3.5 8 0.18 δ1 ~𝑁(0, 50
2) δ31 =  κ ∗ δ1 , κ~G(8, 0.18) 
Table 8. Joint informative prior III: relationship in the form of a random ratio 𝜿, that is gamma-
distributed with the shape and scale parameters specified. 
 
We also summarize and present the properties of each exponential distribution we 
implemented in prior I, and the properties of each gamma distribution we implemented in 
prior III in our simulation in Table 9 and Table 10. The properties of the distributions 
help us to better understand the simulation results in terms of their operating 
characteristics. 
 Difference 
 θ~ exp(λ)  
cp Mean Median Variance 
Prior 1.1 λ = 1 0.1 1 0.3 1 
Prior 1.2 λ = 0.2 0.5 5 1.5 25 
Prior 1.3 λ = 0.13 0.8 7.7 2.3 59 
Prior 1.4 λ = 0.1 1 10 3 100 
Table 9. Characteristics of Exponential distributions implemented in joint informative prior I. 
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 Ratio κ Mean Median Mode Variance Skewness 
Prior 3.1 κ~G(0.5, 33) 16.50 * * 544.50 2.83 
Prior 3.2 κ~G(1, 4.50) 4.50 3.09 0 20.25 2.00 
Prior 3.3 κ~G(2, 1.22) 2.44 2.05 1.22 2.98 1.41 
Prior 3.4 κ~G(3, 0.66) 1.98 1.76 1.32 1.31 1.15 
Prior 3.5 κ~G(8, 0.18) 1.44 1.38 1.26 0.26 0.71 
Table 10.  Characteristics of Gamma distributions implemented in joint informative prior III. 
All the models were fitted in OpenBUGS using a MCMC algorithm, and ran for 
10,000 iterations including 1,000 burn-in samples, with one chain initialized to starting 
values. All results reported here converged unless stated otherwise. 
We estimated the Type I error, mean squared error (MSE), bias, variance, and 
power, for all priors. We also estimated the association between the effects from the two 
stages of the study. The scripts are available in the Appendix. 
3.3 Results 
We compare the Type I error, the MSE, and the power between three dependent 
prior settings with the independent prior setting. For each setting, we also analyze the 
bias, variance, correlation, or a combination of these as needed. For this, we repeat the 
simulations over thousands of scenarios based on different parameter combinations. The 
results are presented below. 
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3.3.1 Results of Joint Informative Prior I 
TYPE I ERROR: All the prior settings led to similar Type I error values. The Type I error 
increases as the inter-stage correlation increases from 0 to 0.4. But we do not find Type I 
error inflation as correlation decreases from 0 to -0.4. This agrees with our expectations 
that, the prior setting matching the data better will result in a better controlled Type I 
error rate. A positive correlation indicates the changes of Stage I and Stage II are similar, 
which results in a small difference between two estimates. However, this does not match 
our prior setting, which is set for the changes of Stage I and Stage II to be different from 
each other. This mismatch leads to a larger Type I error rate. In the other direction, a 
negative correlation implies the difference between the two stages is large. This does 
match our prior settings, and so there is no inflation on the Type I error. In small to 
medium sample sizes, the joint informative priors control Type I error better than the 
independent priors. (Figure 14) 
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Figure 14. Type I error by correlation structure under joint informative prior I, comparing with 
independent priors.  
 
MSE: The difference in the treatment effects between the two stages should be reflected 
in the prior by the mean and the median. In our simulated data, we assume there is no 
difference. Thus, we consider the prior with the smallest mean and median to be the 
scenario where the prior matches the data best, and expect this prior will result in the 
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smallest MSE in both stages under all sample sizes.  The simulation result confirms our 
expectations.  
Among all the informative priors, the prior with 𝜆=1 has the smallest mean and median, 
resulting in the smallest MSE in both stages under all sample sizes. We note that the 
MSE increases as 𝜆 decreases. The priors with 𝜆=1 and 𝜆=0.2 consistently outperform the 
independent priors in terms of MSE in both stages. This shows the benefit of an 
informative prior in this situation. By incorporating the correct information into the 
model, a Bayesian estimator with a joint informative prior has a lower MSE compared to 
the MSE of a model with non-informative priors. Finally, we note that this model is 
robust to all the priors since MSE is acceptably small in all situations. (Figure 15) 
 
Figure 15. The MSE in each stage by correlation structure under joint informative prior I, 
comparing with independent priors.  
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POWER: The independent prior performs slightly better than the others since our 
simulated data assumes no difference between the effects in the two stages, which makes 
the independent setting match the data best. Among all the informative priors, the power 
increases as the rate parameter increases. This also makes sense, because both the median 
and the mean of the exponential distribution decrease as the rate 𝜆 increases. The prior 
with 𝜆=1 has the smallest mean and median, which best matches the data, and therefore 
resulting in the highest power among all others priors. As the rate decreases, both the 
median and mean increasingly deviate from 0, leading to a decrease in power. (Figure 16) 
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Figure 16. Power by correlation structure under joint informative prior I, compared with 
independent priors.  
 
3.3.2 Results of Joint Informative Prior II 
TYPE I ERROR:  The model with independent priors is the most conservative. The 
models with informative priors that assume a relationship between the two stages, on the 
other hand, are less conservative. Under all prior settings, the Type I error is well-
controlled. (Figure 17) 
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Figure 17. Type I error by correlation structure under joint informative prior II, comparing with 
independent prior.  
 
Since the MSE is the sum of bias and variance, looking into bias and variance 
separately may give us better insight on the results. 
 
BIAS: in both Stages, the informative prior with 𝜅=1 has the smallest bias among all the 
informative priors with different r, and behaves very similar to independent priors. This is 
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within our expectation. Our simulated data assumes that the treatment effects are the 
same in both stages. Thus, the prior with 𝜅 =1 matches the data best resulting in the 
smallest bias.  In Stage I, bias increases as the deviation of 𝜅 from 1 increase. The prior 
with 𝜅 less than 1 gives negative bias and the prior with 𝜅 greater than 1 tends to give 
positive bias. This trend is reversed in Stage II. Also, we see that unlike the previous 
statistics, the bias seems to be essentially independent of the sample size. (Figure 18) 
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Figure 18. Bias in each stage by correlation structure under joint informative prior II, comparing 
with independent priors.  
 
VARIANCE: We see the variance of the models decreases as the sample size increases in 
both stages, irrespective of the value r. In both stages, the informative priors have a 
smaller variance than the independent prior. It makes sense that informative priors 
leveraging the pre-study knowledge lead to a more precise estimate than non-informative 
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priors. In Stage I, the variance of the models increased as 𝜅 decreased, but behaved 
exactly the opposite—the variance decreased as 𝜅 decreased—in Stage II. (Figure 19) 
 
Figure 19. Variance in each stage by correlation structure under joint informative prior II, 
comparing with independent priors.  
 
POWER: The data are simulated so that the treatment effect of both stages is the same, 
leading to a 𝜅 of 1. When the 𝜅 of the prior deviates from 1, we expect a corresponding 
loss in power, and this is confirmed in the plots above. We see the power curve of the 
procedure with 𝜅 equal to 1 performs on average better than that of a model with 
independent priors, whereas the power curve of the procedures with 𝜅 different from 1 
are shown to be worse than that of 𝜅 =1, decreasing as 𝜅 deviates from 1. (Figure 20) 
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Figure 20. Power by correlation structure under joint informative prior II, comparing with 
independent priors.  
 
POWER UNDER DIFFERENT ADDITIVE IMPULSES: it makes sense to study how 
the model will perform under different additive impulses. If the additive random variable 
θ has a large variance (10 or 100), it loses its impulse character and will wash away the 
relationship between two stages, resulting in a very low power.  The power is maximized 
when 𝜅=1 under all sample size and inter-stage correlation structures, since the model 
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with 𝜅 =1 matches the data assumption that the ratio of effect sizes is 1. The simulation 
results confirm our prediction. (Figure 21) 
 
Figure 21. Power under different additive impulse 𝜽 by ratio of effect size 𝜿, under joint informative 
prior II, by varying sample size N and the correlation r between the changes in the outcome during 
Stage I and the changes in the outcome during Stage II. 
 
3.3.3 Results of Joint Informative Prior III 
TYPE I ERROR: It is unsurprising that the setting with prior gamma (0.5, 33) inflates the 
Type I error, while all other settings control the Type I error very well. The gamma (0.5, 
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33) is distributed exponentially instead of mounded, which does not help to reflect the 
relationship between the two stages, resulting in an inflated Type I error rate. On the 
other hand, they are less conservative in rejecting the null hypothesis when compared to 
the model with independent priors. (Figure 22) 
 
Figure 22. Type I Error by correlation structure under joint informative prior III, comparing with 
independent priors.  
 
MSE: The data are simulated so that the treatment effect of the two stages is the same, 
leading to a κ of 1. The belief of κ should be reflected by the median of prior distribution. 
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The closer the median of the prior is to 1, the better the performance of the prior will be. 
The distribution of gamma (8, 0.18) has a median of 1.38, which is the closest to 1. 
Gamma (8, 0.18) also has a mode of 1.26 which is again close to 1. Moreover, among all 
the mounded prior settings, gamma (8, 0.18) has the smallest variance and skewness, 
which all contribute to a better performance. Thus, we expected the distribution of 
gamma (8, 0.18) will result in the smallest MSE. When breaking down the MSE into two 
stages, the simulation results agree with our expectations. Among all the gamma 
distributions with shape parameter greater or equal to 1, the setting with the largest shape 
parameter (shape=8) gives the smallest MSE in both stages. As the shape parameter 
decreases from 8 to 1, the MSE increases in both stages. Comparing to other settings, the 
gamma (8, 0.18) has a median of 1.38, which is closest to the true assumption of 1 in our 
data, making it the top performer in terms of the MSE. Also, together with a mode of 
1.26 which is close to 1, the smallest variance, skewness, and kurtosis, it’s in our 
expectation that the setting with prior gamma (8, 0.18) has the lowest MSE in both 
stages. When the shape parameter is smaller than 1, gamma (0.5, 33) in general performs 
not as well as the mounded distributions due to the large variance, skewness, and 
kurtosis.  The large variance, skewness, and kurtosis will stretch out the distribution to 
the right, pulling it away from the assumed κ =1 in our data, thus producing a large MSE 
in both stages. It is also worth noting that the setting with prior gamma (0.5, 33) performs 
slightly better than gamma (1, 4.5) in Stage I. The MSE is always smaller in Stage I than 
Stage II since Stage II has a smaller sample. (Figure 23) 
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Figure 23. The MSE in each stage by correlation structure under joint informative prior III, 
comparing with independent priors. 
 
CORRELATION: the simulation results of the correlation between the effects of the two 
stages also confirms our finding in MSE. The setting with prior gamma (8, 0.18) has the 
largest correlation compared to the others. Correlation decreases as the shape parameter 
decreases. The setting with prior gamma (0.5, 33) has the smallest correlation between 
the two stages. A prior setting matching the data better would enforce a stronger 
correlation between the estimated effects of the two stages. (Figure 24) 
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Figure 24. Correlation of the effects from two stages by correlation structure under joint informative 
prior III.  
 
POWER: Among all the mounded gamma distributions (shape parameter greater or equal 
to 1), the power increases as the shape parameter increases from 2 to 8.  The setting with 
the prior gamma (8, 0.18) performs best, giving power similar to that of the independent 
priors. The setting with prior gamma (1, 4.5) is a slightly under powered when sample 
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size is small but can be powered greater than 80% when the sample size is increased. The 
data assumes the effectiveness of the two stages are the same, leading to a κ of 1. The 
distribution of gamma (8, 0.18) has a median of 1.38, which is the closest to 1. Gamma 
(8, 0.18) also has a mode of 1.26 which is again close to 1. Moreover, among all the 
mounded prior settings, gamma (8, 0.18) has the smallest variance, skewness, and 
kurtosis, which all contribute to a better performance. It is very interesting that gamma 
(0.5, 33) performs well comparing to the other mounded distributions. It may be that 
when the gamma distribution is exponentially shaped and is asymptotic to both the 
vertical and horizontal axes, there is no peak drop off and the power isn’t reduced. 
Moreover, as expected, the power for the same model increased with an increase in the 
underlying sample size. (Figure 25) 
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Figure 25. POWER by correlation structure under joint informative prior III, comparing with 
independent priors.  
 
Lastly, as we discussed before, in this setting, our method should be able to 
provide a good estimation of the ratio κ. To demonstrate this, we applied different 
Gamma distributions as the choice of prior on κ to the two different data structures, 
assuming the true ratio κ of the Stage II effect to the Stage I effect equals 1 and 2 in each 
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data structure respectively. Remember that, based on the simulation results, we concluded 
that in setting III, a gamma prior with a small variance that’s not heavily tailed will 
perform well if the median of the resulting distribution matches the true structure of the 
data, and thus should be selected for the model. So, we expect the prior gamma (8, 0.18) 
will have the best estimation of κ for the dataset when the true ratio is 1, and the prior 
gamma (2, 1.22) will have the best estimation of κ for the dataset when the true ratio is 2. 
The results shown in Figure 26 and Figure 27 below give us the same recommendations 
as expected. The gamma (8, 0.18) gives the most accurate estimate of κ with narrow CI in 
all sample sizes when the true ratio in the dataset is 1, whereas gamma (2, 1.22) gives the 
most accurate estimation of κ with the smallest MSE in all sample size when the true 
ratio in the dataset is 2. We performed these estimations under all the correlation 
structures and obtained the same recommendation in each case. For simplicity, only the 
result with r=0.2 is presented here.  
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Figure 26. The estimation of 𝜿 under different settings in prior III by sample size with true 𝜿=1. 
 
Figure 27. The estimation of 𝜿 under different settings in prior III by sample size with true 𝜿=2.  
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3.4 ADAPT-A Trial Example  
We applied the proposed method to ADAPT-A trial data. We fitted these data using 
the Bayesian full probability model with the dependent informative priors in setting III. 
The results are presented in Table 11. We assigned two different priors driven by 
different beliefs based on the historical evidence: if the treatment effects are the same in 
both stages, or if the effect in Stage II is twice as large as that in Stage I.  From the results 
we see that, the informative priors lead to a larger estimate of the overall treatment effect, 
and a smaller SD, thus make the overall effect significant at 0.05 level. Figure 28 shows 
the posterior densities of the κ, from models with two different prior distributions:(1) 
Gamma (2,1.22) and (2) Gamma (8,0.18) on κ, respectively. From the graph we can see 
that, the distribution of the posterior simulations of κ on the left are highly constrained by 
the prior distribution of Gamma (2, 1.22). By comparison, the graph on the right shows 
that the prior is “less informative” since it does not appear to be constraining the posterior 
inference as much.    
Informative Prior 
δ31 = κ ∗ δ1 
Overall 
Estimate 
SD of Overall 
Estimate 
κ Estimate 
mean/median 
P-value* 
κ ~Gamma (2, 1.22) -1.372 0.7596 2.273/1.985 0.0332 
κ ~Gamma (8, 0.18) -1.485 0.8337 1.474/1.426 0.0392 
Table 11. Incorporate joint informative priors to estimate treatment effect using ADAPT trial data. 
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Figure 28. Histograms of posterior densities of the estimation 𝜿, from models with two different prior 
distributions:(left) Gamma (2,1.22) and (right) Gamma (8,0.18) on 𝜿. 
 It should also be noted that the ADAPT trial data includes missing data on both 
outcome responses and covariates. In our application, for missing response, we assume 
the missing responses are MCAR (Missing Completely At Random) or MAR (Missing At 
Random). So, the Bayesian model will impute the missing response as the posterior 
prediction from the model fitted to the observed data. For the missing covariates, we 
build a ‘prior model’ as an imputation model to impute them. The OpenBUGS code is 
available in the Appendix.  
3.5 Conclusions 
We proposed a way to quantify the relationship between the effects from the two 
stages, while accounting for uncertainties. We examined the sensitivity of our Bayesian 
joint full probability model to the choice of priors that are used to encode the different 
prior beliefs about this relationship into the model. Incorporation of prior information 
provides additional structure to the data, which improves the estimation of the 
coefficients. The simulation study showed that, in most common situations, our method 
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displayed similar or improved performance to previous existing approaches. For small to 
medium sample sizes, the method proposed here gave better control of Type I error. 
Though our proposed method generated a slightly larger MSE, this was not so much a 
flaw in our method but rather a result of the natural tendency for Bayesian methods to 
account for more variability and to estimate more parameters. In the sensitivity study, we 
showed that by incorporating prior information, the Bayesian model with the right choice 
of priors offered a better controlled Type I error, a smaller MSE, and comparable power 
to independent prior setting. The correct informative prior could also provide a good 
estimation of the relationship between the estimates from two stages.  
Our proposed method can easily be extended to binary outcomes. Moreover, our 
Bayesian model is able to handle missing data. As an application of the method proposed 
in this chapter, we assumed the missing response data are MCAR or MAR, and built a 
‘prior model’ to impute the missing data in covariates. Extensions can also be made in the 
future to explicitly model any known data missing mechanisms. To summarize, we 
believe that our approach offers a competitive alternative for the analysis of data from 
SPCD trials. The OpenBUGS and R scripts used in conducting this research are available 
from the author.  
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CHAPTER FOUR: WEIGHTED APPROACHES WITH PLACEBO RESPONSE 
AS CONTINUOUS CHARACTERISTIC FOR THE ANALYSIS OF SPCD DATA 
4.1 Introduction 
As noted by Rybin et al. [12], misclassification is a concern when the patients are 
simply classified as “placebo responders” and “placebo non-responders” after Stage I in a 
SPCD trial based on the observed data in Stage I. Since the estimation of Stage II 
treatment effect is based on data from ‘placebo non-responders’, the misclassification of 
patients after Stage I may introduce bias in the estimated treatment effect.  
By this binary classification criterion, the subjects receiving placebo in Stage I are 
defined as “non-responders” only if the outcome at the end of Stage I is both greater than 
a pre-set threshold according to expert’s knowledge and the improvement of their Stage I 
outcome measure is less than a fixed percentage compared to baseline. The weaknesses 
of this criterion-based classification approach are three-fold. Firstly, the hard-cutoff 
percentage of improvement implies a truncation of the response measure. For example, in 
ADAPT-A trial based on MADRS score, investigators set the criterion to classify 
subjects receiving placebo during Stage I. The criterion defines the placebo responders 
after Stage I as patients that show an improvement at least 50% over baseline and having 
an outcome measure that is greater than a preset threshold of 16 [6] [17] .  By this 
criterion, subjects with 51% improvement would be classified as ‘placebo responders’, 
and subjects with 49% improvement would be classified as ‘placebo non-responders’, 
even though the difference in improvement is relatively minor. If the outcome data has a 
bimodal distribution and separated by the ratio of outcome of 50%, this approach might 
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be fine. However, if the distribution of the outcome data is unimodal or uniform, the 
approach is suspect. Secondly, although the preset threshold is set according to expert 
knowledge, but may not be necessarily correct. Thirdly, the measurement error can play a 
large role in determining the placebo response. Fava in 2003 [6] stated that measurement 
error or, simply, poor sensitivity of the instrument can contribute to observing a placebo 
response. Later on, Rybin et al. [13] showed that, the more prevalent and larger 
measurement errors lead to higher misclassification.   
To assess how the criterion-based classification approach to placebo response 
affects the estimation of treatment effects in SPCD, we use the ADAPT-A trial data as an 
example. The results are presented in Table 12. We kept threshold 16 as the same but 
varied the cutoff criterion from 60% to 40% and calculated Stage II treatment effect using 
the Bayesian joint full probability model approach proposed in Chapter 2. A 10% change 
in cutoff resulted in a change of 1.02 in the mean and a change of 0.11 in the SD in 
placebo non-responders of the data.  
Criterion Cutoff Placebo Responders  
Mean (SD) 
Placebo non-responders  
Mean (SD) 
40% -2.43 (1.76)  -3.78 (1.12)  
50% -2.44 (1.77)   -2.76 (1.13)  
60% -2.26 (1.56) - -2.88 (1.24)  
Table 12. SPCD Stage II treatment effect estimates under different criteria for selecting placebo 
responders. 
Several methods have been proposed to better handle the misclassification of 
placebo responders and non-responders in SPCD trials. For instance, Rybin et al. [12] 
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proposed a weighted propensity score (WPS) method as well as a weighted K-mean 
clustering (WKMC) method based on the repeated measure model. The two methods are 
similar in that they both include Stage II placebo subjects accordingly to their weight, but 
they differ from each other in how they estimate this weight. Now, we propose two new 
Bayesian models in which the Stage II placebo data are weighted. Instead of applying a 
binary classification scheme, we treat “placebo response” as a continuous characteristic 
that is present to some degree in every patient. This approach may more accurately 
represent the placebo effect. In practice, the placebo non-response profile is unknown and 
will need to be estimated for each subject. 
In this chapter, we view the placebo response as a latent characteristic of subjects 
that cannot be directly measured. We propose a statistical model to estimate this 
characteristic along with a measure of uncertainty. Based on Bayesian full joint 
probability model proposed in Chapter 2, we will present two new approaches that differ 
in how they incorporate this estimation of placebo response.  
We will also provide a solution to block the so-called feedback. In Bayesian 
analysis, the “feedback” is taken to be the phenomenon where certain parameters 
appearing in one of the terms in the likelihood indirectly inform quantities in another 
term in the likelihood, due to the fact that the posterior distribution of these parameters 
depends on both terms [18] [20]. Specifically, in our situation, the “placebo response” 
characteristic is applied to all observations in the second stage, but the estimation of this 
characteristic is based only on the observation’s baseline value and Stage I outcome. 
Smeeth et al. [21] used a cohort study to assess in one case how the “feedback” in 
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Bayesian analysis might influence model estimation. They studied the impact of statins 
on a variety of health outcomes in a matched cohort study of UK patients. In the 
statistical analysis, PS (Propensity Score) techniques was applied. The researchers 
conducting the study used data from the Health Improvement Network database (THIN) 
database containing computerized medical records from general practices in the UK. The 
study aimed to test if statins can reduce the risk of stroke when compared with untreated 
patients. A survival analysis was conducted; concurrently the PS technique was used to 
adjust for the possible confounding factors between statins and stroke. Therefore, two 
equations of the same model are used: one for the survival analysis, and one for the PS. 
These researchers estimated the effect using three methods: MLE, BAYESIAN PS, and 
BAYESIAN PS NO FEEDBACK, and the comparisons of the results are shown in Table 
13. For the “MLE”, the frequentist estimation approach of the treatment effect, the PS 
techniques proceed in two stages. The PS model is fitted by maximum likelihood firstly, 
the result of which is then substituted in place of the true PS in an outcome survival 
model. In contrast, the “BAYESIAN PS” analysis calculates the posterior distribution for 
the PS from the PS model and the treatment effect from the survival model at the same 
time. However, without blocking the "feedback", a consequence of this approach is that 
the data in the survival model can produce feedback that influences the estimated PS. 
This method makes a tradeoff between fitting the survival model and the PS model. As an 
improvement, the “BAYESIAN PS NO FEEDBACK” method applies proper technique 
to block the "feedback", resulting in a better estimation. The results in Table 13 reveal 
that the estimates from BAYESIAN PS NO FEEDBACK are in close agreement with 
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those from the MLE. Thus, feedback from the survival model has been eliminated. In 
fact, the point estimates of treatment effect from MLE and BAYESIAN PS NO 
FEEDBACK must be asymptotically equivalent because of the well-known large sample 
frequency matching properties of Bayesian with non-informative priors and maximum 
likelihood estimates; whereas the estimate derived from BAYESIAN PS without 
eliminating feedback is typically a bit off from that obtained by MLE. 
Analysis method Log Hazard Ratio (SE) 
Treatment Effect 
MLE -0.127 (0.049) 
BAYESIAN PS -0.149 (0.051) 
BAYESIAN PS NO FEEDBACK -0.137 (0.051) 
Table 13. Log hazard ratios for the statin treatment in THIN data. 
This chapter consists of four sections. In the first section, the methodology and 
the models for the proposed methods are presented. In the second section, an extensive 
simulation study is conducted to compare the performance of our methods to existing 
methods.  A sensitivity study is conducted to evaluate the robustness of our methods in 
handling misclassification compared with the previous methods conducted under the 
binary classification scheme. In the third section, we use proposed models to analyze 
ADAPT-A trial data, and the results are compared to those obtained using existing 
methods. The conclusion and discussion make up the last section. In this paper, unless 
otherwise stated, we use lowercase letters to represent data vectors as well as single 
random variables, and uppercase letters to represent data matrices. We use bolded letters 
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to denote sets of random variables. For example, 𝒁 = {𝑧0, 𝑧3, 𝑧6} 𝑎𝑛𝑑 𝜮 = {𝜎1
2, 𝜎2,1
2 , 𝜎2,1
2 } 
etc. 
4.2 Methodology 
4.2.1 SPCD Design and Parametrization 
As discussed in the Chapter 1, there are several variants of the SPCD; the one we 
applied is a design where all of the Stage I placebo patients are re-randomized to be on 
placebo or drug in Stage II. We note that this chapter differs from the Chapter 2 and 
Chapter 3 in that we will include more subjects into the estimation of the Stage II effect 
by using all re-randomized Stage I placebo subjects and the weighted estimation for the 
Stage II effect. This approach utilizes the data more efficiently and may improve the 
precision of the estimate and increase the power. On Figure 29 we present the 
parametrization of this model. In this model, all patients have the outcome 𝑧0 measured at 
baseline, and are randomized to either placebo or drug in the first stage. The typical 
composition of this randomization is 2:1 for placebo vs. drug. After Stage I, we measure 
and denote the mean change in the outcome by 𝛿0 for subjects on placebo, and by (𝛿0 +
𝛿1) for subjects on drug. In Stage II, the patients who were on placebo in Stage I are re-
randomized to either placebo or drug at a 1:1 ratio, while patients assigned to the active 
drug in Stage I are kept on drug in Stage II. Outcome 𝑧2 is measured at the end of Stage 
II. Among the Stage I placebo patients, 𝛿2 is the mean change for patients on placebo, 
whereas (𝛿2 + 𝛿20) is the mean change for patients on drug. So, the parameters 𝛿1 and 
𝛿20 are the magnitude of the treatment effects in Stage I and Stage II, respectively.  We 
estimate the overall treatment effect as a weighted average of the two stages: 𝛿 = 𝜈 ∗
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𝛿1 + (1 − 𝜈) ∗ 𝛿20, and the choice of the SPCD weight 𝜈 can be chosen to optimize the 
power for a given treatment allocation [11].  
 
Figure 29. Parameterization of SPCD with all Stage I placebo patients re-randomized. 
 
4.2.2 Estimation of Placebo Non-response  
Recall that in previous SPCD studies, we have commonly defined non-responders 
as subjects after Stage I for whom the improvement of their outcome measure is less than 
a fixed percentage compared to baseline and their Stage I outcome is above a certain 
fixed nonresponse threshold. For example, Fava et al [6] chose 50% as the minimum 
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improvement and 16 as the nonresponse threshold for MADRS. Under this definition, the 
placebo response status is defined explicitly based on the fixed threshold and the change 
in the outcome measure from baseline in subjects treated with placebo. However, simple 
classification of subjects as placebo responders or placebo non-responders based on this 
change is susceptible to misclassification. In general, we want to define placebo response 
as a characteristic that is, to some extent present in each participant of the trial. So, 
instead of only focusing on the “placebo/non-responders” for the estimation in Stage II, 
we include everyone from the placebo arm in Stage I, and weigh them accordingly. This 
characteristic can be viewed as a “weight” for the subject’s contribution to the treatment 
effect estimates in Stage II. By applying those weights on all of the Stage I placebo 
subjects, the estimation of treatment effect in Stage II will be corrected/adjusted for 
likelihood of placebo response. This is done by attempting to give each subject their 
proper amount of influence over the parameter estimates. Actually, the common method 
of classifying patients described before, is equivalent to assigning the subjects who 
satisfy the criteria a weight of 1 and placebo responders a weight of 0. Thus, the common 
0/1 classification strategy can be seen as a special case of this more general and 
quantitative approach.  
If this characteristic is known or measurable, we can scale it to range from 0 to 1 
so that a higher score corresponds to a higher placebo non-response. However, in reality, 
the placebo response characteristic is an unknown quantity. We propose a way to 
estimate it. As we mentioned before, typically the individual placebo response status has 
been defined as a binary character with 1 representing responders and 0 representing non-
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responders based on experts’ belief. We know that a subject’s response to placebo can be 
affected by a number of factors such as age, gender, disease history, baseline values, and 
improvement percentage [22]. Therefore, we propose to use a logistic regression model 
that predicts the probability of a subject being a responder to placebo based on the 
available characteristics. We believe the probability of being a responder can be predicted 
by the baseline value, the percentage of improvement, the treatment assignment in Stage 
I, as well as the interactions of baseline value, the percentage of improvement, and the 
treatment assignment. The model we propose is given below: 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝜃1 + 𝜃2 ∗ 𝑧0,𝑖 + 𝜃3 ∗ 𝑄𝑖 + 𝜃4 ∗ 𝑇1,𝑖 + 𝜃5 ∗ 𝑧0,𝑖 ∗ 𝑇1,𝑖 + 𝜃6 ∗ 𝑄𝑖 ∗ 𝑇1,𝑖 (1) 
where 𝑧0,𝑖 is the baseline value, 𝑧1,𝑖 is the Stage I outcome, 𝑄𝑖 = (
𝑧1,𝑖
𝑧0,𝑖
) is the percentage 
of improvement, 𝑇1,𝑖 is the treatment in Stage I, and 𝑝𝑖 is the probability of being a 
responder for a subject i. From this, we can use 𝑝𝑖 as an estimate of the placebo response 
status for subject i, ranging from 0 to 1, with scores close to 0 corresponding to a lower 
placebo non-response and scores close to 1 corresponding to a higher placebo non-
response. This 𝑝𝑖 serves as the basis for our weighting approaches.  
4.2.3 Proposed Bayesian Weighted Variance Model  
Consider a SPCD data that consists of three observations on a continuous 
outcome measure for each subject: the baseline value 𝑧0, the outcome from Stage I 𝑧1, 
and the outcome from Stage II 𝑧2. Since we are interested in outcome changes, we use 𝑦1 
= 𝑧1 − 𝑧0 and 𝑦2 = 𝑧2 − 𝑧1 as the responses in the model. We also have the variables 𝑇1 
and 𝑇2 representing the treatment assignment for each subject in Stage I and Stage II 
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respectively, taking on the value of 1 for drug and 0 for placebo. The proposed 
parameterization is shown in Figure 29. The overall SPCD treatment effect is still defined 
as a weighted average of effect of Stage I and Stage II; but, unlike the previous model, 
now the treatment effect of Stage II is estimated from both placebo non-responders and 
placebo responders, and are denoted as 𝛿22 𝑎𝑛𝑑 𝛿24 respectively.  
We propose two weighted models to analyze these data. These two models differ 
in how they incorporate the “weight”. We call the first one the “weighted variance 
model”, in which the Stage II response variance is inversely proportional to the placebo 
response status “weight”.  An observation with small error variance will receive a large 
weight since it contains relatively more information than an observation with large error 
variance, which will receive a relatively smaller weight. The second model is called the 
adjusted model in which “weight” is considered as a covariate and thus can be adjusted in 
the regression.  
The formulation for the weighted variance model is presented:   
Response model for the estimation of the probability being responder: 
Likelihood           𝑅 ~ 𝐵𝑒𝑟𝑛(𝑝𝑖) 
Model 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝜃1 + 𝜃2 ∗ 𝑧0,𝑖 + 𝜃3 ∗ 𝑄𝑖 + 𝜃4 ∗ 𝑇1,𝑖 + 𝜃5 ∗ 𝑧0,𝑖 ∗ 𝑇1,𝑖 + 𝜃6 ∗ 𝑄𝑖 ∗ 𝑇1,𝑖 (1) 
Regression part for the outcome: 
Stage I          Likelihood       𝑦1𝑖 ~ 𝑁(𝜇1𝑖, 𝜎1
2) 
                   Model             𝜇1𝑖 = 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗ + 𝛿1 ∗ 𝑇1𝑖 (2) 
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Stage II         Likelihood       𝑦2𝑖 ~ 𝑁(𝜇2𝑖, 𝜎2
2 ∗ 𝑝𝑖,𝑇1𝑖
−1 )    
                   Model              𝜇2𝑖 = 𝛽1,𝑇1𝑖 + 𝛽2,𝑇1𝑖 ∗ 𝑧1𝑖
∗ +  𝛿2,𝑇1𝑖 ∗ 𝑇2𝑖, (3) 
𝑤𝑖𝑡ℎ 𝑖 = 1: 𝑛, 𝑇1𝑖 = 0 𝑜𝑟  1, 𝑎𝑛𝑑 𝑝𝑖,0 = 𝑝𝑖, 𝑝𝑖,1 = 1 
In the above formulas,  𝑇1𝑖 is the treatment assignment for each subject in Stage I 
with the value 0 for placebo and 1 for drug. 𝑧0𝑖
∗ , 𝑧1𝑖
∗  are the centered baseline values in 
Stage I and Stage II. 𝑄𝑖 = (
𝑧1,𝑖
𝑧0,𝑖
) is the percentage of improvement. Here 𝑛 stands for the 
total number of subjects. In the first stage, we assume a constant variance 𝜎1
2 for each 
subject. However, in the second stage, each observation of a subject who was on placebo 
in Stage I, is given its own variance factor 𝜎2
2 ∗ 𝑝𝑖,0
−1, which is a weighted variance by 𝑝𝑖 
estimated in (1). Meanwhile, the observations of subjects on drug in both stages have the 
constant variance 𝜎2
2 as 𝑝𝑖,1 is always assigned 1. The estimated contrast of interest is 
𝛿 = 𝜈 ∗ 𝛿1 + (1 − 𝜈) ∗ 𝛿20, which represents the overall treatment effect. The treatment 
effect for each group is summarized in Table 14.   
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 Mean Structure Variance Structure 
Stage I D 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗ + 𝛿1 𝜎1
2 
Stage I P 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗  𝜎1
2 
Stage II D taking P in Stage I 𝛽1,0 + 𝛽2,0 ∗ 𝑧1𝑖
∗ + 𝛿2,0 𝜎2
2 ∗ 𝑝𝑖
−1 
Stage II P taking P in Stage I 𝛽1,0 + 𝛽2,0 ∗ 𝑧1𝑖
∗  𝜎2
2 ∗ 𝑝𝑖
−1 
Stage II D taking D in Stage I 𝛽1,1 + 𝛽2,1 ∗ 𝑧1𝑖
∗ +𝛿2,1 𝜎2
2 
Treatment Effect in Stage I 𝛿1  
Treatment Effect in Stage II 𝛿2,0  
Table 14. Treatment effects summarized by group under proposed weighted variance model. 
4.2.4 Prior Specification for Weighted Variance Model 
The Bayesian approach allows for the incorporation of prior beliefs into the 
model. The prior distribution captures the external knowledge of the experiment, helping 
us to quantify the uncertainty of the unknown parameters. Bayesian inference is based on 
a combination of prior and observed data information (the likelihood). Our model is 
specified with non-informative independent priors. In our weighted variance model, the 
priors are assigned as 𝛼1 ~ 𝜋1
𝛼 , 𝛼2 ~𝜋2
𝛼 ,  𝛽1,0~𝜋10
𝛽
 , 𝛽1,1~ 𝜋11
𝛽
, 𝛽2,0~𝜋20
𝛽
, 𝛽2,1~𝜋21
𝛽 , 
𝛿1~𝜋1
𝛿 , 𝛿2,0~𝜋20
𝛿 , 𝛿2,1~𝜋21
𝛿 ,
1
𝜎1
2  ~ 𝜋1
𝜎 ,
1
𝜎2,1
2  ~ 𝜋21
𝜎 ,
1
𝜎2,2
2  ~ 𝜋22
𝜎 , 𝜃1~𝜋1
𝜃 , 𝜃2~𝜋2
𝜃 , 𝜃3~𝜋3
𝜃 , 
𝜃4~𝜋4
𝜃 , 𝜃5~𝜋5
𝜃 , 𝜃6~𝜋6
𝜃. Here 𝜋 stands for a general distribution.  
4.2.5 Cutting Feedback in Weighted Variance Approach 
However, the potential feedback problem needs to be taken into consideration. 
The “feedback” is present in our approach. This is because we have two equations. The 
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first equation is for estimating the placebo response, and the second equation is for 
estimating the treatment effects.  These two equations are fitted simultaneously rather 
than sequentially, based on the same posterior distribution [18]. So, the data in the second 
equation indirectly inform the estimation of the placebo response in the first equation. 
But this influence is not desired. So proper technique is needed to block the feedback. To 
illustrate this, write data = {(𝑍𝑖 , 𝑇𝑖, 𝑅𝑖)*; i ∈ 1 : n} to denote our SPCD dataset. The 
posterior density for model parameters (𝜶, 𝜷, 𝛅, 𝜽, 𝜮) is 
𝑝(𝜶, 𝜷, 𝜹, 𝜽, 𝜮|𝒁, 𝑻, 𝑹)  ∝ 𝐿(𝒁, 𝑻, 𝑹|𝜶, 𝜷, 𝜹, 𝜽, 𝜮) ∗ 𝜋(𝜶, 𝜷, 𝜹, 𝜽, 𝜮) (4) 
with prior density 𝜋(𝜶, 𝜷, 𝜹, 𝜽, 𝜮) and likelihood function  
𝐿(𝒁, 𝑻, 𝑹|𝜶, 𝜷, 𝜹, 𝜽, 𝜮) = 𝑙1(𝒁, 𝑻|𝜶, 𝜷, 𝜹, 𝜮, 𝜽) ∗ 𝑙2(𝑹, 𝒁|𝜽)     (5) 
which is the product of the likelihood functions 𝑙1𝑎𝑛𝑑 𝑙2 for the outcome and responder 
estimation model respectively. To estimate the treatment effect 𝛅 , we sample from the 
posterior distribution for model parameters using MCMC. The calculation proceeds in 
two iterative steps: Firstly, we impute the pi from model (1) by updating from the 
conditional distribution of 𝜽, denoted as 𝑝(𝜽|𝜶, 𝜷, 𝜹, 𝜮, 𝒁, 𝑻, 𝑹). Secondly, given the 
imputed 𝑝𝑖, we fit the joint outcome models (2) and (3) by updating from the conditional 
distribution of the outcome model parameters 𝑝(𝜶, 𝜷, 𝜹, 𝜮|𝜽, 𝒁, 𝑻, 𝑹). The feedback from 
the outcome model is a consequence of the conditional distribution for 𝜽, which is given 
by 
𝑝(𝜽|𝜶, 𝜷, 𝜹, 𝜮, 𝒁, 𝑻, 𝑹) ∝  𝑙1(𝒁, 𝑻|𝜶, 𝜷, 𝜹, 𝜮, 𝜽) ∗ 𝑙2(𝑹, 𝒁|𝜽) ∗ 𝜋(𝜽) (6) 
The estimation of treatment effect depends on the 𝑝𝑖  via the variance component 𝜎2
2 ∗
𝑝𝑖
−1. And all the estimations of the parameters in (3) are depend on the variance 
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component. Therefore, metropolis updates of 𝜽 will to some extent be influenced by the 
estimated value of 𝜷, 𝑎𝑛𝑑 𝜹.  
A method introduced by Lunn et al. [23] was proposed for cutting feedback when 
fitting complex Bayesian models using MCMC. Briefly, the posterior distribution is still 
expressed as a correct decomposition of conditional distributions for model parameters, 
but during posterior updating we do not update from the full conditionals. The procedure 
discounts the likelihood contribution from different data sources to ensure that the model 
components are fitted separately. The cutting feedback approach can be implemented by 
OpenBUGS language.  
Applying the method from Liu et al, we cut feedback between the responder 
estimation model (1) and outcome models (2) and (3) by not updating from the full 
conditional distribution for 𝛉. The correct conditional densities for 𝑝(𝜽|𝜶, 𝜷, 𝜹, 𝜮, 𝒁, 𝑻, 𝑹) 
is given in equation (6). To cut feedback, we update from the approximate conditional 
distribution  
𝑝(𝜽|𝜶, 𝜷, 𝜹, 𝜮, 𝒁, 𝑻, 𝑹) ∝  𝑙2(𝑹, 𝒁|𝜽) ∗ 𝜋(𝜽) (7) 
which ignores the likelihood contribution from the outcome model (2) and (3). Again, the 
procedure can be implemented in OpenBUGS.  
4.2.6 Proposed Bayesian Adjusted Model 
As we mentioned before, by using a different way of incorporating the “weight”, 
we arrive at another model called the adjusted model.  
The formulation for the adjusted model is presented:   
Response model for the estimation of probability being responder: 
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Likelihood                         𝑅 ~ 𝐵𝑒𝑟𝑛(𝑝𝑖) 
Model 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖) = 𝜃1 + 𝜃2 ∗ 𝑧0,𝑖 + 𝜃3 ∗ 𝑄𝑖 + 𝜃4 ∗ 𝑇1,𝑖 + 𝜃5 ∗ 𝑧0,𝑖 ∗ 𝑇1,𝑖 + 𝜃6 ∗ 𝑄𝑖 ∗ 𝑇1,𝑖 (1) 
Regression part for the outcomes: 
Stage I          Likelihood       𝑦1𝑖 ~ 𝑁(𝜇1𝑖, 𝜎1
2) 
                    Model             𝜇1𝑖 = 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗ + δ1 ∗ 𝑇1𝑖 (8) 
Stage II         Likelihood       𝑦2𝑖 ~ 𝑁(𝜇2𝑖, 𝜎2,𝑇1𝑖
2 ) 
                Model           𝜇2𝑖 = 𝛽1,𝑇1𝑖 + 𝛽2,𝑇1𝑖 ∗ 𝑧1𝑖
∗ +  𝛿2,𝑇1𝑖 ∗ 𝑇2𝑖 + 𝜁𝑇1𝑖 ∗ 𝑝𝑖,𝑇1𝑖 ,   (9) 
𝑤𝑖𝑡ℎ 𝑖 = 1: 𝑛, 𝑇1𝑖 = 0 𝑜𝑟  1, 𝑎𝑛𝑑 𝑝𝑖,0 = 𝑝𝑖 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑖𝑛 (1), 𝑝𝑖,1 = 0 
Here,  𝑇1𝑖, 𝑧0𝑖
∗ , 𝑧1𝑖
∗ , 𝑄𝑖and 𝑛 have the same definitions as in the weighted variance 
model. For the variance structure, we assume constant variance 𝜎1
2 for each subject in 
Stage I,  𝜎2,0
2  for Stage II subjects who were on placebo in Stage I, and 𝜎2,1
2  for Stage II 
subjects who were on drug in Stage I. In the second stage, for the re-randomized placebo 
subjects, we adjusted the regression by incorporating the probability 𝑝𝑖 as a covariate. 
The estimated contrast of interest is 𝛿 = 𝜈 ∗ 𝛿1 + (1 − 𝜈) ∗ 𝛿20, which represents the 
overall treatment effect. Treatment effects for each group are summarized in Table 15.   
 Mean Structure Variance 
Structure 
Stage I D 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗ + 𝛿1 𝜎1
2 
Stage I P 𝛼1 + 𝛼2 ∗ 𝑧0𝑖
∗  𝜎1
2 
Stage II D taking P in Stage I 𝛽1,0 + 𝛽2,0 ∗ 𝑧1𝑖
∗ + 𝜁0 ∗ 𝑝𝑖 + 𝛿2,0 𝜎2,0
2  
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Stage II P taking P in Stage I 𝛽1,0 + 𝛽2,0 ∗ 𝑧1𝑖
∗ + 𝜁0 ∗ 𝑝𝑖 𝜎2,0
2  
Stage II D taking D in Stage I 𝛽1,1 + 𝛽2,1 ∗ 𝑧1𝑖
∗ + 𝛿2,1 𝜎2,1
2  
Treatment Effect in Stage I 𝛿1  
Treatment Effect in Stage II 𝛽2,0  
Table 15. Treatment effects summarized by group under proposed adjusted model. 
 
4.2.7 Prior Specification and Cutting Feedback for Adjusted Model 
Similar to the weighted variance model, for our adjusted model, the priors are 
assigned as 𝛼1 ~ 𝜋1
𝛼 , 𝛼2 ~𝜋2
𝛼 , 𝛽1,0~𝜋10
𝛽
, 𝛽1,1~ 𝜋11
𝛽
, 𝛽2,0~𝜋20
𝛽
, 𝛽2,1~𝜋21
𝛽
, 𝛿1~ 𝜋1
𝛿 ,   
𝛿2,0~ 𝜋20
𝛿 , 𝛿2,1~ 𝜋21
𝛿 , 
1
𝜎1
2  ~ 𝜋1
𝜎 ,
1
𝜎2,1
2 ~ 𝜋21
𝜎 ,
1
𝜎2,2
2 ~ 𝜋22
𝜎 , 𝜃1~𝜋1
𝜃 , 𝜃2~𝜋2
𝜃 , 𝜃3~𝜋3
𝜃 ,   
 𝜃4~𝜋4
𝜃 , 𝜃5~𝜋5
𝜃 , 𝜃6~𝜋6
𝜃 , 𝜁0~𝜋0
𝜁
, 𝜁1~𝜋1
𝜁
. As before, here 𝜋 stands for a general 
distribution.  
Also, the same technique is applied to the adjusted model to cut feedback.  The 
posterior density for model parameters (𝜶, 𝜷, 𝛅, 𝜻, 𝜽, 𝜮) is 
𝑝(𝜶, 𝜷, 𝜹, 𝜻, 𝜽, 𝜮|𝒁, 𝑻, 𝑹)  ∝ 𝐿(𝒁, 𝑻, 𝑹|𝜶, 𝜷, 𝜹, 𝜻, 𝜽, 𝜮) ∗ 𝜋(𝜶, 𝜷, 𝜹, 𝜻, 𝜽, 𝜮) (10) 
with prior density 𝜋(𝜶, 𝜷, 𝜹, 𝜻, 𝜽, 𝜮) and likelihood function  
𝐿(𝒁, 𝑻, 𝑹|𝜶, 𝜷, 𝜹, 𝜻, 𝜽, 𝜮) = 𝑙1(𝒁, 𝑻|𝜶, 𝜷, 𝜹, 𝜻, 𝜮, 𝜽) ∗ 𝑙2(𝑹, 𝒁|𝜽) (11) 
which is the product of the likelihood functions 𝑙1 and 𝑙2 for the outcome and responder 
estimation model respectively. To cut the feedback, we update from the approximate 
conditional distribution  
    𝑝(𝜽|𝜶, 𝜷, 𝜹, 𝜻, 𝜮, 𝒁, 𝑻, 𝑹) ∝  𝑙2(𝑹, 𝒁|𝜽) ∗ 𝜋(𝜽) (12) 
which ignores the likelihood contribution from the outcome models (8) and (9). 
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Implementation: 
The Markov Chain Monte Carlo (MCMC) algorithms are implemented in the 
OpenBUGS software to generate simulated observations from the posterior distribution 
of the unknown quantities in the statistical model. With sufficiently many simulated 
observations, it is possible to get an accurate picture of the posterior distribution. The 
summary diagnostic statistics are computed from these draws.  
4.2.8 Simulation Study  
We performed a large simulation study to assess the operating characteristics to 
allow for the comparison of the proposed weighted variance method as well as the 
proposed adjusted method, and the non-weighted Bayesian method proposed in Chapter 
2.  
When generating the data, the parameter values for the simulation study were 
chosen based on the results of a recent clinical trial in a psychiatric population that used 
MADRS as an outcome [11]. We still generate the data under the SPCD parameterization 
in 0, where patients on placebo in Stage I were classified as “responders” and “non-
responders” after Stage I.  This way, the treatment effect in Stage II of the 
parameterization in Figure 29 can be seen as a mixed effect from placebo responders and 
placebo non-responders. The mean and standard deviation of the outcome at baseline 
were set to 31 and 5, respectively. The SD of the change from baseline to the end of 
Stage I and the SD of the change from baseline to the end of Stage II were both set to 7. 
The correlation between the baseline and the changes in both Stage I and Stage II was set 
to 0.1. “Non-responders” were defined as subjects for whom the outcome at the end of 
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Stage I is both at least half the baseline value and above the fixed threshold of 16. The 
non-response rate was set to 0.75. The mean change in Stage II among subjects on drug 
in Stage I was assumed to be 60% smaller than the corresponding mean change in Stage 
I. We set a 2:1 randomization in favor of placebo in Stage I, and a 1:1 re-randomization 
in Stage II among all subjects who were on placebo in Stage I. The following total 
sample sizes were considered: 75, 90, 120, 150, and 300. The inter-stage correlations 
between the changes in the outcome during Stage I and the changes in the outcome 
during Stage II were set to be the same for all treatment arms and ranges from −0.4 to 0.4 
in 0.1 increments. The SPCD effective weight 𝜈 is chosen typically from 0.5 to 0.8, and 
we picked 0.7 for our simulation [12]. For power calculation, the treatment effects 
𝛿1, 𝛿31, and 𝛿32 need to be selected appropriately. We assume 𝛿31 = 𝑐 ∗ 𝛿32, and we 
assess the power by varying 𝑐 from 0 to 2. We also vary the SPCD effective weight 𝜈 
from 0.7 to 0.5 for power assessment. The values of 𝛿1,𝛿31, and 𝛿32were set to 0 for 
assessing Type I error. By giving a prescribed non-response rate 𝑝𝑁𝑅, the parameter 𝛿0, 
𝛿01, and 𝛿02 can be calculated using the formulas developed in [11]. 
In the prior settings, the non-informative independent priors for the unknown 
parameters of the weighted variance model of interest are specified as follows: 
  𝛼1, 𝛼2, 𝛽1,0, 𝛽1,1, 𝛽2,0, 𝛽2,1, 𝛿1,𝛿2,0, 𝛿2,1~𝑁(0, 50 
2), 𝜃1, 𝜃2, 𝜃3~𝑁(0, 0.1),
𝜃4, 𝜃5, 𝜃6~𝑁(0, 50 
2),
1
𝜎1
2 ,
1
𝜎2,1
2 ,
1
𝜎2,2
2  ~ 𝐺(10
−3, 10−3). The non-informative independent 
priors are specified for the unknown parameters of the adjusted model of interest as 
follows: 𝛼1, 𝛼2, 𝛽1,0, 𝛽1,1, 𝛽2,0, 𝛽2,1, 𝛿1, 𝛿2,0, 𝛿2,1, 𝜁0, 𝜁1~𝑁(0, 50 
2), 𝜃1 … 𝜃3~𝑁(0, 0.1), 
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𝜃4 … 𝜃6~𝑁(0, 50 
2),
1
𝜎1
2 ,
1
𝜎2,1
2 ,
1
𝜎2,2
2  ~ 𝐺(10
−3, 10−3). The non-informative independent 
priors are specified for the unknown parameters in the non-weighted Bayesian model of 
interest as follows: 𝛼1, 𝛼2, 𝛽11, 𝛽12, 𝛽21, 𝛽22, 𝛽31, 𝛽32, 𝛿1, 𝛿11, 𝛿21, 𝛿31~ 𝑁(0, 50 
2), 
1
𝜎1
2 ,
1
𝜎21
2 ,
1
𝜎22
2 ,
1
𝜎23
2 ~ 𝐺(10
−3, 10−3). Here 𝑁 stands for the normal distribution with mean 
and precision specified, and G stands for the Gamma distribution with shape and rate 
specified.  
We also conduct a sensitivity study, to measure the robustness of our proposed 
methods in terms of the misclassification. We performed an extensive simulation study to 
assess the operating characteristics under the different settings of misclassifications in our 
model by comparing the results against those obtained from the non-weighted model. The 
settings of misclassification are presented in Table 16.  
Recall that the responders are defined as subjects for whom the outcome at the 
end of Stage I is both at least half the baseline value and above a fixed nonresponse 
threshold of 16. We generated our data according to this definition. Misclassification can 
happen either because the percentage of change is wrong, the threshold is wrong, or both 
are wrong. Now we consider different settings of misclassification caused by either 
possibility. For this sensitivity study, we only consider sample sizes of 75, 120, and 150. 
Setting Percentage of change Threshold 
Data generation 50% 16 
Misclassification scenario 1 60% 16 
Misclassification scenario 2 50% 10 
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Misclassification scenario 3 40% 16 
Misclassification scenario 4 50% 20 
Misclassification scenario 5 40% 20 
Table 16. Misclassification settings in defining responders in SPCD data. 
4.3 Results  
Results from simulations are given below. We considered over many scenarios for 
each of the parameter setting combinations. We also considered a representative set of 
misclassification scenarios. For clarity and brevity of presentation, we only present 
scenario 1 and scenario 2. The results of other scenarios are available in the appendix.  
The important trends and conclusions observed from the results are discussed in the 
following section. 
4.3.1 Performance of the Weighted Variance Model and the Adjusted Model 
TYPE I ERROR: The simulation results shows that for the small sample size, the 
unweighted model has a comparable lower Type I error while the adjusted model has a 
slight inflation in Type I error. But the weighted variance model preserved type I error 
pretty well. This is true cross all correlation structures. As sample size increases, the new 
proposed procedures performed on par with the unweighted model, having a Type I error 
around desired value 0.025. (Figure 30) 
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Figure 30. Type I error by correlation structure. Bayesian weighted variance model; Bayesian 
adjusted model; non-weighted Bayesian model developed in Chapter 2. 
 
MSE: The MSE is consistently lower for the new proposed methods comparing to non-
weighted method. It is true for all the sample size and correlation structures. For the small 
to median sample size, the weighted variance method gives the smallest MSE. As sample 
size increases to fairly large, the weighted variance method and the adjusted method 
behave very similarly but are still better than the non-weighted method. We also note that 
the MSE of all methods exhibited quadratic dependency on the correlation, reaching a 
maximum when the correlation is 0 and decreasing as the correlation between the two 
stages increases. This is the expected behavior, as we know that when the correlation is 
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nonzero, Stage I and Stage II can interact and lead to a more precise estimation.  (Figure 
31) 
 
Figure 31. MSE by correlation structure. Bayesian weighted variance model; Bayesian adjusted 
model; non-weighted Bayesian model developed in Chapter 2. 
 
POWER: the power assessment in Figure 32 shows that, under the situation that the 
effect size was assumed to be the same in responders and non-responders, i.e. 𝛿32 = 𝑐 ∗
𝛿31 𝑤𝑖𝑡ℎ 𝑐 = 1 and the effect size is comparably high (0.5 SD), the two new proposed 
methods performed similarly but slightly better than the non-weighted method. In this 
situation, under all the combinations of correlation and sample size, all the methods could 
be successfully powered at least 70%. Power increased as sample size increased under 
any correlation structure.  
  
91 
When it comes to the results in Figure 33, the power assessed with a lower SPCD 
effective weight,  𝜈 (0.5), for the Stage I treatment effect, our proposed the weighted 
variance and the proposed adjusted method benefit a lot than the non-weighted method. 
At each sample size, the power for the new procedures are about 5% higher than the non-
weighted Bayesian method. This confirms the advantage of our new methods. By 
including more subjects who proportionally contribute to the estimation of the second 
stage effect, our proposed methods are more robust in the Stage II estimation.   
When it comes to the result in Figure 34, power assessment varies as  𝑐 goes from 0 to 2. 
The result is also within our expectation. When the placebo responders demonstrate a 
higher response compared with placebo non-responders in the second stage (𝑐 > 1), the 
proposed methods always have higher power than non-weighted method. This is due to 
the fact that the non-weighted method effectively assigns zero weight to placebo 
responders in the second stage. When the placebo responders demonstrate a lower 
response compared with placebo non-responders, (𝑐 = 0.5), in view that 120 is a fairly 
median large sample size, the non-weighted method has low power (<80%) while our 
new proposed methods are powered properly. This gain in power also comes from the 
fact that the proposed weighted variance method and the adjusted method include the 
placebo responders instead of excluding them like the non-weighted method.  
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Figure 32. Power 0.5SD with 𝒄 =1 and SPCD effective weight 𝝂=0.7 by correlation structure and 
sample size. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
  
93 
 
Figure 33. Power 0.5SD with 𝒄 =1 and SPCD effective weight 𝝂=0.5 by correlation structure and 
sample size. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
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Figure 34. Power 0.5SD with fixed sample size 120, SPCD effective weight 𝝂=0.7 and varying 𝒄 by 
correlation structure. Bayesian weighted variance model; Bayesian adjusted model; non-weighted 
Bayesian model developed in Chapter 2. 
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4.3.2 Sensitivity Analysis of the Result to the Misspecification of the Definition of 
Placebo Responders  
For the sensitivity study, we compared the robustness of the proposed methods to 
the non-weighted Bayesian method in terms of the Type I error, the MSE, the bias, the 
variance and the power, among the considered scenarios that misclassification may occur. 
The results of scenario 1 and scenario 2 are presented and discussed below. The results of 
the other scenarios are presented in the appendix.  
TYPE I ERROR: When the model uses the 60% improvement instead of the 50% 
improvement criterion to classify subjects into responders and non-responders, that will 
lead to a misclassification. In this situation, our weighted variance method and adjusted 
method inflate the Type I error by a small amount for the small sample size, while the 
non-weighted method always exhibited a lower Type I error. But as the sample size 
increases, the new proposed weighted variance method and adjusted method can preserve 
the Type I error fairly well, while the non-weighted method is still relatively more 
conservative.  It is true for all the correlation structures. This is within our expectation. 
By using the 60% improvement criterion, the models tend to classify more subjects into 
placebo responders. Thus, for the non-weighted method, less subjects contribute to the 
estimation of treatment effect in Stage II, which results in a conservative Type I error 
rate. However, the new proposed methods are more robust to this misclassification. By 
including placebo responders into the estimation of the treatment effect in Stage II, 
accordingly to their weights, both weighted variance method and adjusted method can 
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balance this misclassification. More subjects contribute to the estimation and so it is 
easier to reject the null hypothesis, resulting in an inflated Type I error. (Figure 35) 
 
Figure 35. Type I error by correlation structure with misclassification of 60% improvement for 
responders. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
 
MSE: under the same scenario of misclassification using an improvement of 60% instead 
of 50%, the new proposed new methods reduced the MSE significantly compared to the 
non-weighted method. This is again due to the advantages of the new proposed methods 
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which estimate the weight for each placebo subjects and include them according to their 
weights in the second stage analysis as opposed to exclude them totally. The proposed 
weighted variance method and the adjusted method are robust to the misclassification as 
measured by their MSE. (Figure 36) 
 
Figure 36. MSE by correlation structure with misclassification of 60% improvement for responders. 
Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian model 
developed in Chapter 2. 
Since MSE is the sum of bias and variance, exploring the impacts of the bias and 
variance separately may give us greater insights.  
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BIAS: in Stage I, the weighted variance and the adjusted methods exhibited a positive 
bias whereas the non-weighted method exhibited a negative bias. All the methods 
produced relatively small bias (~10−2), nevertheless the magnitudes of bias from the 
proposed methods are smaller than those of the non-weighted method. In Stage II, all the 
methods gave a positive bias. The non-weighted method had the smallest bias, while the 
weighted variance method and the adjusted method behaved similarly. Also, in the 
second stage, the bias decreased as inter-stage correlation increased. (Figure 37) 
 
Figure 37. Bias in each stage by correlation structure with misclassification of 60% improvement for 
responders. Bayesian weighted variance model; Bayesian adjusted model; Non-weighted Bayesian 
model developed in Chapter 2. 
 
VARIANCE: With respect to variance, in both stages, the variance is reduced by the 
weighted methods. In Stage I, the Bayesian weighted method gave the smallest variance 
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while non-weighted method gave the largest variance. But in general, the variance is 
small enough under all methods. In Stage II, the proposed methods reduced the variance 
significantly comparing to the non-weighted method. The weighted variance method and 
the adjusted method performed similarly and outperformed the unweighted method for all 
sample sizes. There is always a variance-bias tradeoff. Though the proposed weighted 
methods showed a slightly higher bias in Stage II relatively to the non-weighted method, 
by including the placebo responders according to the different weights, the two proposed 
weighted methods reduced the variance significantly in the second stage. (Figure 38) 
 
 
Figure 38. Variance in each stage by correlation structure with misclassification of 60% 
improvement for responders. Bayesian weighted variance model; Bayesian adjusted model; non-
weighted Bayesian model developed in Chapter 2. 
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POWER: under the same scenario of misclassification using improvement of 60% instead 
of 50%, the simulation result shows that the new proposed weighted variance method and 
adjusted method outperformed the non-weighted method for all sample size in terms of 
power. The adjusted method produced slightly higher power than weighted variance 
method for small sample size but the two methods performed very similarly for larger 
sample sizes. This is true for all correlation structures. Since using 60% instead of 50% 
improvement criterion, the non-weighted method tends to classify less subjects as 
placebo non-responders which are the only arm contributing to the treatment effect in the 
Stage II. This will impair its power to some extent. However, the new proposed methods 
are more robust in terms of their power relative to sample sizes since no matter what, all 
placebo subjects will contribute to the second stage estimation. The classification 
criterion will only influence how much (weight) they can contribute.   (Figure 39) 
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Figure 39. Power by correlation structure with misclassification of 60% improvement for 
responders. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
 
TYPE I ERROR: When the model uses 10 instead of 16 as threshold to classify subjects 
into responders and non-responders, that will lead to misclassification. In this situation, 
our weighted variance method and adjusted method inflated the Type I error for small 
sample sizes, while the non-weighted method showed a lower Type I error. But as the 
sample size increases, the weighted variance method and the adjusted method can 
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preserve the Type I error fairly well, whereas the non-weighted method tended to be 
conservative.  This was the case for all the correlation structures. This result was not 
surprising. By using a threshold of 10, the models tended to classify more subjects as 
placebo responders. Thus, for the non-weighted method, fewer subjects contributed to the 
estimation of the treatment effect in Stage II, which resulted in a conservative Type I 
error rate. However, the proposed methods are more robust to this misclassification. By 
including placebo responders into the estimation of the treatment effect in Stage II, 
accordingly to their weights, both the weighted variance method and the adjusted method 
can balance this misclassification. More subjects contribute to the estimation and so it is 
easier to reject the null hypothesis, resulting in an inflated Type I error.  (Figure 40) 
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Figure 40. Type I Error by correlation structure with misclassification of threshold=10 for 
responders. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
 
MSE: under the same scenario of misclassification using 10 as the threshold instead of 
16, the proposed methods reduced MSE significantly comparing to the non-weighted 
method. It is also due to the advantages of the proposed methods which estimate the 
weight for each placebo subject and include them according to their weights in the second 
stage analysis rather than excluding them altogether. The proposed weighted variance 
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method and the adjusted method are robust against misclassification in the sense of their 
MSE are not significantly inflated by misclassification. (Figure 41) 
 
Figure 41. MSE by correlation structure with misclassification of threshold=10 for responders. 
Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian model 
developed in Chapter 2. 
Again, it makes sense to look at bias and variance separately since MSE is a 
combination of the two. 
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BIAS: in Stage I, the weighted variance and the adjusted methods gave the positive bias 
and the non-weighted method gave the negative bias. All the methods give small bias 
(~10−2), but the magnitudes of the bias from the proposed methods are smaller than the 
non-weighted method. In Stage II, all the methods give a positive bias. For small sample 
sizes, all three methods are very close with regard to bias. As the sample size increases, 
the proposed methods gave smaller bias than the non-weighted method analysis. Also, in 
the second stage, the bias decreased as the inter-stage correlation increased. (Figure 42) 
 
Figure 42. Bias in Stage I and Stage II by correlation structure with misclassification of threshold=10 
for responders. Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian 
model developed in Chapter 2. 
 
VARIANCE: we can see that in both stages, the variance is smaller in the weighted 
methods. In Stage I, the weighted variance method always gave the smallest variance 
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while non-weighted method gave the largest variances. In Stage II, the proposed methods 
reduced the variance significantly compared to the non-weighted method. The weighted 
variance method and the adjusted method performed similarly and both outperformed the 
unweighted method for all sample sizes. The proposed methods are more robust to the 
variance compared to the non-weighted method when misclassification occurs due to the 
use of wrong threshold. For the same reason, unlike the non-weighted method, all 
placebo subjects contributed to the estimation in the Stage II in the weighted variance 
method and the adjusted method. The classification criterion only influenced how much 
(weight) they could contribute. But for the non-weighted method, misclassification may 
lead to a larger change in the number of placebo non-responders, leading to less precise 
estimations. (Figure 43) 
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Figure 43. Variance in Stage I and Stage II by correlation structure with misclassification of 
threshold=10 for responders. Bayesian weighted variance model; Bayesian adjusted model; non-
weighted Bayesian model developed in Chapter 2. 
 
POWER: under the same scenario of misclassification using a threshold of 10 instead of 
16, the simulation results show that the weighted variance method and the adjusted 
method outperform the non-weighted method for all sample size when measured by their 
statistical power. The adjusted method produced slightly higher power than the weighted 
variance method. This is the case for all correlation structures. When using a threshold of 
10 instead of 16, the non-weighted method tended to classify fewer subjects into placebo 
non-responders, which is the only arm contributing to the treatment effect in Stage II. 
This will impair the power to some extent. However, the proposed methods are more 
robust in terms of power since all placebo subjects will contribute to the estimation in 
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Stage II. The classification criteria will only influence how much (weight) they can 
contribute. (Figure 44) 
 
Figure 44. Power by correlation structure with misclassification of threshold=10 for responders. 
Bayesian weighted variance model; Bayesian adjusted model; non-weighted Bayesian model 
developed in Chapter 2. 
4.4 ADAPT-A Trial Example   
We applied the proposed methods to the data from the ADAPT-A trial. The 
individual weights for each subject in Stage II were estimated via the response model 
Error! Reference source not found.. The binary placebo nonresponse in model Error! 
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Reference source not found. was defined at the end of Stage I as less than a 50% 
decrease in MADRS total score from baseline and a MADRS score greater than 16. The 
results from the weighted variance model and the adjusted model, compared to the result 
obtained from non-weighted model are summarized in Table 17. By all methods, we 
observed no significant treatment effect based on the overall weighted outcome. For the 
weighted variance method, the effect as shown is estimated with 95% credible interval to 
be -1.054 (-2.806, 0.7136), while for the adjusted method, the estimate is -1.037 (-2.795, 
0.7391). Comparing those to the result of non-weighted method -1.036 (-2.866, 0.795), 
by including more subjects according to their individualized contributions in the analysis 
for the second stage, the two new proposed methods gave smaller standard deviations, 
thus resulting in more precisely overall estimations. History, autocorrelation, and density 
plots, presented in Figure 45 and Figure 46, are used to assess convergence of the 
sampler for the weighted variance method and the adjusted method respectively. Visual 
inspection of the time series plot produced by “history” suggests that the Markov chains 
have converged. The histogram of the posterior samples of the mean looks symmetrical 
for all the treatment effects. The autocorrelation also seems to have disappeared after first 
10 lags, proving efficient inferences for our models.  There have been claims that there is 
issue with convergence when applying the method we provided for blocking the feedback 
in Bayesian estimates [24]. The claim comes from the scenario that the posterior density 
of the parameter will converge to different densities using different samplers. To show 
our models don’t have this problem, we use different samplers for MCMC. As Figure 47 
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shows that for our methods, the estimates converged very well under all different 
samplers.  
Method Stage I 
Estimate 
Stage II 
Estimate 
 
Overall 
Estimate 
SD of 
overall 
estimate 
P-value* 
Non-weighted -0.302 -2.749 -1.036 0.9257 0.1309 
Weighted Variance -0.320 -2.768 -1.054 0.8969 0.1206 
Adjusted -0.306 -2.744 -1.037 0.9004 0.1233 
Table 17. ADAPT-A estimates of treatment effects comparison based on three methods using 
ADAPT real data. 
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Figure 45. History, density and auto correlation of estimates, treatment effect in Stage I, II, and 
overall by the weighted variance method. 
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Figure 46. History, density and auto correlation of estimates, treatment effect in Stage I, II, and 
overall by the adjusted method. 
  
Figure 47. Posterior density of overall treatment effect with different samplers, using the weighted 
variance model (left) and the adjusted model (right). 
It should also be noted again that the real ADAPT trial data includes missing data. 
We use the same methods mentioned in Chapter 2 to handle missing data.  
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4.5 Conclusion  
We proposed two new Bayesian weighted models to analyze SPCD data. They 
differ from each other in how they incorporate the “weight”. The proposed methods 
overcome the weakness of the criterion-based binary classification of placebo non-
responders and responders. The simulation study showed that, by including more subjects 
in the second stage estimation according to their individualized contribution (i.e., 
weight), our proposed methods are more robust against the misclassification of 
responders, and therefore give smaller MSE and larger power. Especially when the data 
is distributed unimodal or evenly, a reliable and accurate criterion is difficult to come by, 
our methods are more powerful and arguably have a solid advantage over the non-
weighted Bayesian method. This is confirmed by the results under the scenarios of 
misclassification. We provided a way to cut the feedback in estimates which usually 
happens when some of the parameters need to be estimated sequentially in Bayesian 
diagram. Our methods have no convergence problem when cutting feedback. Moreover, 
our Bayesian models are able to handle missing data. As an application of the method 
proposed in this paper, we build a ‘prior model’ to impute the missing data in Stage I and 
Stage II outcomes. To summarize, we believe that our approach offers a competitive 
alternative for the analysis of data from SPCD trials. The two proposed models have pros 
and cons. The weighted variance model has a smaller variance and bias when 
misclassification occurs, and is easier to interpret as a weighted method. But this 
approach takes more time in computation. On the other hand, the adjusted model has a 
slightly higher power when misclassification occurs. It takes less time in computation. 
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But for adjusted method, the interpretation of the weight is not as intuitive. When 
computational efficiency is not a concern, we prefer the weighted variance approach. The 
OpenBUGS and R scripts used in conducting this research are provided in the Appendix.  
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CHAPTER FIVE: SUMMARY AND FUTURE STUDIES 
5.1 Summary 
A strong placebo response in psychiatric disorders has been noted for the past 50 
years. The contributing factors to placebo response include diagnostic misclassification, 
issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to 
change, measurement errors, poor quality of data entry and verification, waxing and 
waning of the natural course of illness, regression toward the mean phenomenon, patient 
and clinician expectations about the trial, study design issues, non-specific therapeutic 
effects, and high attrition [6]. Over the past several years, researchers have attempted to 
reduce the placebo effect in a variety of ways. But due to the limited knowledge of the 
mechanisms and the extent of placebo response, most approaches showed little or no 
benefit, until Fava et al [6] proposed the Sequential Parallel Comparison Design (SPCD), 
a new study design that has successfully reduced the placebo effect. 
We proposed a new Bayesian full probability model for analyzing the SPCD trial 
data to complement of the existing methods. The method improves over the existing 
methods: the method provides a direct full probability model that can reflect the true 
likelihood of the data and allow us to estimate the treatment effects in both stages 
simultaneously; it utilizes all the data collected in the SPCD trial; and it offers the 
flexibility to incorporate prior’s information.  The simulation study showed that, in most 
common situations, our method displayed similar or improved performance compared 
with previous existing approaches. For small to medium sample sizes, the method 
proposed here gave better control of Type I error. Though our proposed method 
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generated a slightly larger MSE, it was not so much a flaw in our method but rather a 
consequence of the natural tendency of Bayesian methods to account for more variability 
and to estimate more parameters.   
The relationship between the treatment effects from the two stages is worth 
investigation. As we know, SPCD is a design with two stages. In SPCD, the overall 
treatment effect is measured as a weighted average of the treatment effects from the two 
stages, and these two effects are derived from data measured on the same patients. The 
study conducted by Fava et al [6] concluded that because of the within-patient 
correlation, the treatment effect in Stage II is directly related to the treatment effect in 
Stage I. This relationship cannot be arbitrarily chosen when designing a trial. The 
methods for analyzing SPCD data ignore this association, and therefore leave room for 
improvement. Based on the Bayesian full probability model, we proposed a way to 
quantify and estimate this relationship. we propose to use informative dependent priors to 
reflect our knowledge about the existence and nature of the relationship between the 
treatment effects from the two stages in SPCD. Even better, our model is sufficiently 
flexible that we can propose different settings of dependent priors to assess this 
relationship, and inform us on which choice of priors captures features of the real data 
better. In the simulation study we showed that, our method with the right choice of 
dependent priors offered a better controlled Type I error, a smaller MSE, and comparable 
power to vague independent prior setting. The correct informative prior could also 
provide a good estimation of the relationship between the treatment effect from two 
stages. 
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There is also a debate on how to quantify the placebo response. The previous 
researchers treated the placebo response as binary characteristic, which could be 
calculated directly based on the pre-set criterion. So, after Stage I, patients who were on 
placebo in Stage I are classified as either “placebo responders” or “placebo non-
responders”. However, due to the complexity of the driving forces behind a placebo 
response, we believe the placebo response should be modeled as a continuous 
characteristic that is present to some degree in every patient, and it cannot be measured 
directly. Instead, our inference about placebo response has to be probabilistic. Simply 
classifying subjects in to “responders” or “non-responders” will lead to misclassification. 
We proposed a probabilistic model to estimate this characteristic along with a measure of 
its uncertainty. Based on this new concept of placebo response, we further proposed two 
new approaches: the weighted variance method and the adjusted method, to analyze 
SPCD data. These two methods differ in how they incorporate this estimation of the 
placebo response. The simulation study showed that, by including every placebo subjects 
in the second stage estimation according to their individualized contribution, the new 
methods are more robust against the misclassification of responders over the non-
weighted approach, and therefore give smaller MSE and larger power. We also provided 
a way to block the feedback in estimates which usually happens when some of the 
parameters need to be estimated sequentially in the Bayesian diagram.  
 There are still many unknowns about the placebo response. For example, it has 
been reported that in cardiology or oncology, there is super-response to treatment. It is 
assumed to be associated with a specific genetic profile. But this is still an ongoing study 
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and no definitive conclusion has been made so far [25] [26] [27]. In order to better 
understand the placebo response and meaningfully address it, more research is needed in 
both on the biological underpinnings as well as the design of clinical trials and the 
analysis methodology. We believe the methods proposed in this dissertation can offer 
some useful ideas on this journey.   
5.2 Future Studies 
There is still a lot of open questions in the study of placebo response under SPCD. 
This dissertation work can be extended in several aspects.  
Firstly, our Bayesian full probability model is able to handle missing data. The 
ADAPT-A trial data used in an application of the proposed method has missing response. 
OPENBUGS imputes values from the posterior predictive distribution for the missing 
data under the assumption that the data are missing completely (or mostly) at random 
(MCAR or MAR). Under this assumption, the missing mechanism is ignorable, so the 
probability of data being missing does not depend on observed or unobserved data. 
However, the most general and most complex missing data scenario is missing not at 
random (MNAR). In an MNAR model, the probability that a value is missing can depend 
not only on other observed quantities but also on the unobserved observations (the 
would-have-been values). The missing mechanism is no longer ignorable. Non-ignorable 
missingness introduces fundamental identifiability issues; by virtue of the fact that we did 
not observe the missing data, we have no data with which to estimate its distribution. 
Under MNAR, a model for missing mechanism is required in order to make correct 
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inferences about the model parameters [28] [29]. Extensions can also be made in the 
future to explicitly model any known missing data mechanisms [30] [31] [32].  
Secondly, it is a natural choice to develop a model which can combine the 
improvements in Chapter 3 and 4. A Bayesian joint model which can not only include all 
the placebo subjects accordingly to their contributions but also can provide an estimation 
of the relationship between the treatment effects from two stages.     
Lastly, instead of assuming the placebo response as a continuous characteristic and 
estimating it by a probabilistic model, we can view it as a latent binary characteristic. 
This way, we observe the outcome in all placebo subjects without knowing the actual 
placebo response status of each individual. Thus, the sample distribution of the Stage I 
outcome can be viewed as an unlabeled mixture of two distributions: one for “placebo 
responders”, and the other one for “placebo non-responders”. The Bayesian framework 
can offer several ways to estimate parameters in a mixed distribution with a latent 
variable [33] [34].  
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APPENDIX 
Simulation Results of Misclassification Scenarios 3, 4 and 5 for Responders  
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.0274 0.0271 0.0232 
-0.3 0.0265 0.0272 0.0232 
-0.2 0.0267 0.0263 0.0234 
-0.1 0.0265 0.0272 0.0239 
0.0 0.0263 0.0270 0.0238 
0.1 0.0271 0.0273 0.0240 
0.2 0.0277 0.0273 0.0241 
0.3 0.0276 0.0273 0.0242 
0.4 0.0276 0.0275 0.0238 
120 -0.4 0.0268 0.0266 0.0229 
-0.3 0.0267 0.0269 0.0233 
-0.2 0.0264 0.0265 0.0233 
-0.1 0.0267 0.0268 0.0232 
0.0 0.0262 0.0271 0.0231 
0.1 0.0268 0.0274 0.0234 
0.2 0.0268 0.0279 0.0234 
0.3 0.0263 0.0278 0.0236 
0.4 0.0261 0.0267 0.0243 
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150 -0.4 0.0241 0.0237 0.0249 
-0.3 0.0244 0.0236 0.0250 
-0.2 0.0252 0.0238 0.0248 
-0.1 0.0253 0.0245 0.0243 
0.0 0.0258 0.0244 0.024 
0.1 0.0261 0.0243 0.0244 
0.2 0.0257 0.0249 0.0246 
0.3 0.0262 0.0246 0.0242 
0.4 0.0262 0.024 0.0245 
Table 18. Type I error by correlation structure with misclassification of scenario 3 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
 
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 1.7688 1.7767 1.9433 
-0.3 1.7803 1.7898 1.9615 
-0.2 1.7876 1.7983 1.9734 
-0.1 1.7907 1.8023 1.9788 
0.0 1.7897 1.8018 1.9779 
0.1 1.7846 1.797 1.9706 
0.2 1.7753 1.7878 1.957 
0.3 1.7617 1.774 1.9369 
0.4 1.744 1.7558 1.9104 
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120 -0.4 1.1037 1.1063 1.1995 
-0.3 1.111 1.1153 1.2104 
-0.2 1.1157 1.1211 1.2175 
-0.1 1.1177 1.124 1.2207 
0.0 1.1171 1.124 1.2202 
0.1 1.1139 1.121 1.2157 
0.2 1.108 1.1151 1.2075 
0.3 1.0995 1.1063 1.1954 
0.4 1.0883 1.0944 1.1795 
150 -0.4 0.885 0.885 0.9581 
-0.3 0.8909 0.8924 0.9668 
-0.2 0.8947 0.8973 0.9725 
-0.1 0.8963 0.8998 0.975 
0.0 0.8959 0.8998 0.9745 
0.1 0.8933 0.8975 0.9709 
0.2 0.8886 0.8928 0.9643 
0.3 0.8817 0.8857 0.9545 
0.4 0.8727 0.8761 0.9417 
Table 19. MSE by correlation structure with misclassification of scenario 3 for responders. Proposed 
Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-weighted 
Bayesian model. 
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Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.741 0.7412 0.7172 
-0.3 0.7388 0.737 0.7127 
-0.2 0.7381 0.737 0.7091 
-0.1 0.7363 0.7366 0.7075 
0.0 0.7354 0.7367 0.707 
0.1 0.7377 0.738 0.7076 
0.2 0.7403 0.7399 0.7103 
0.3 0.7431 0.7435 0.7147 
0.4 0.7487 0.7484 0.7183 
120 -0.4 0.9073 0.9122 0.8969 
-0.3 0.9051 0.9099 0.894 
-0.2 0.9034 0.908 0.8911 
-0.1 0.902 0.9064 0.8919 
0.0 0.9031 0.9073 0.8918 
0.1 0.9044 0.9084 0.8931 
0.2 0.907 0.9111 0.8948 
0.3 0.9109 0.9144 0.8972 
0.4 0.9124 0.9176 0.901 
150 -0.4 0.9592 0.9626 0.9448 
-0.3 0.9586 0.9613 0.9434 
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-0.2 0.9584 0.9614 0.9427 
-0.1 0.9578 0.9601 0.9425 
0.0 0.9585 0.9605 0.9426 
0.1 0.9589 0.9605 0.9441 
0.2 0.96 0.9612 0.9457 
0.3 0.9611 0.9629 0.9483 
0.4 0.9635 0.9659 0.9501 
Table 20. Power by correlation structure with misclassification of scenario 3 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
 
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.0269 0.0266 0.0259 
-0.3 0.0278 0.0272 0.0262 
-0.2 0.027 0.0267 0.0258 
-0.1 0.0272 0.0269 0.0258 
0.0 0.0273 0.0269 0.0261 
0.1 0.0271 0.0268 0.0266 
0.2 0.0274 0.0267 0.0265 
0.3 0.0278 0.0267 0.0271 
0.4 0.028 0.0278 0.0274 
120 -0.4 0.026 0.0261 0.0251 
-0.3 0.0252 0.0262 0.0251 
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-0.2 0.0256 0.0262 0.0253 
-0.1 0.026 0.0264 0.0255 
0.0 0.0263 0.0269 0.0253 
0.1 0.0263 0.0265 0.0246 
0.2 0.0266 0.0266 0.0243 
0.3 0.0267 0.027 0.0252 
0.4 0.027 0.0269 0.0258 
150 -0.4 0.0241 0.0248 0.0234 
-0.3 0.0244 0.0248 0.0242 
-0.2 0.0242 0.0247 0.0254 
-0.1 0.0248 0.0243 0.0261 
0.0 0.0241 0.0247 0.0251 
0.1 0.0252 0.0247 0.0255 
0.2 0.0252 0.0246 0.0259 
0.3 0.0251 0.0249 0.0263 
0.4 0.0242 0.0242 0.0262 
Table 21. Type I error by correlation structure with misclassification of scenario 4 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
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Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 1.7623 1.7815 2.8205 
-0.3 1.7738 1.7935 2.8641 
-0.2 1.7811 1.8012 2.892 
-0.1 1.7843 1.8047 2.9043 
0.0 1.7834 1.804 2.9009 
0.1 1.7783 1.799 2.8819 
0.2 1.7692 1.7898 2.8473 
0.3 1.7558 1.7763 2.797 
0.4 1.7383 1.7584 2.7309 
120 -0.4 1.1008 1.1091 1.5746 
-0.3 1.1081 1.1169 1.5982 
-0.2 1.1128 1.122 1.6134 
-0.1 1.1149 1.1243 1.6201 
0.0 1.1144 1.124 1.6184 
0.1 1.1112 1.1209 1.6081 
0.2 1.1054 1.115 1.5894 
0.3 1.0969 1.1065 1.5622 
0.4 1.0858 1.0951 1.5265 
150 -0.4 0.8829 0.8879 1.2287 
-0.3 0.8888 0.8942 1.2469 
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-0.2 0.8926 0.8983 1.2586 
-0.1 0.8943 0.9002 1.2638 
0.0 0.8939 0.8999 1.2624 
0.1 0.8914 0.8975 1.2545 
0.2 0.8867 0.8928 1.24 
0.3 0.8799 0.8859 1.219 
0.4 0.8709 0.8768 1.1915 
Table 22. MSE by correlation structure with misclassification of scenario 4 for responders. Proposed 
Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-weighted 
Bayesian model. 
 
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.7449 0.7428 0.589 
-0.3 0.7422 0.7396 0.5801 
-0.2 0.7406 0.738 0.5789 
-0.1 0.7385 0.736 0.5785 
0.0 0.7388 0.7358 0.5777 
0.1 0.7398 0.7356 0.58 
0.2 0.743 0.7389 0.5854 
0.3 0.7456 0.7404 0.5927 
0.4 0.7489 0.7447 0.6041 
120 -0.4 0.9114 0.9123 0.8075 
-0.3 0.9075 0.9094 0.7996 
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-0.2 0.9071 0.9081 0.7951 
-0.1 0.9059 0.9076 0.7928 
0.0 0.9056 0.9081 0.7962 
0.1 0.907 0.9088 0.7991 
0.2 0.9094 0.9102 0.8025 
0.3 0.9123 0.9127 0.8094 
0.4 0.9162 0.9181 0.819 
150 -0.4 0.9622 0.964 0.8801 
-0.3 0.9607 0.9617 0.8755 
-0.2 0.9598 0.9606 0.8733 
-0.1 0.9596 0.9602 0.8728 
0.0 0.9596 0.9599 0.8718 
0.1 0.9598 0.9607 0.8729 
0.2 0.9608 0.9617 0.877 
0.3 0.9623 0.9628 0.8807 
0.4 0.9649 0.9649 0.885 
Table 23. Power by correlation structure with misclassification of scenario 4 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
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Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.0269 0.0266 0.0259 
-0.3 0.0278 0.0272 0.0262 
-0.2 0.027 0.0267 0.0258 
-0.1 0.0272 0.0269 0.0258 
0.0 0.0273 0.0269 0.0261 
0.1 0.0271 0.0268 0.0266 
0.2 0.0274 0.0267 0.0265 
0.3 0.0278 0.0267 0.0271 
0.4 0.028 0.0278 0.0274 
120 -0.4 0.026 0.0261 0.0251 
-0.3 0.0252 0.0262 0.0251 
-0.2 0.0256 0.0262 0.0253 
-0.1 0.026 0.0264 0.0255 
0.0 0.0263 0.0269 0.0253 
0.1 0.0263 0.0265 0.0246 
0.2 0.0266 0.0266 0.0243 
0.3 0.0267 0.027 0.0252 
0.4 0.027 0.0279 0.0258 
150 -0.4 0.0231 0.0238 0.0234 
-0.3 0.0234 0.0238 0.0242 
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-0.2 0.0232 0.0237 0.0254 
-0.1 0.0238 0.0243 0.0261 
0.0 0.0241 0.0247 0.0251 
0.1 0.0252 0.0247 0.0255 
0.2 0.0252 0.0246 0.0259 
0.3 0.0251 0.0249 0.0263 
0.4 0.0242 0.0242 0.0262 
Table 24. Type I error by correlation structure with misclassification of scenario 5 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
 
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 1.7623 1.7815 2.8205 
-0.3 1.7738 1.7935 2.8641 
-0.2 1.7811 1.8012 2.892 
-0.1 1.7843 1.8047 2.9043 
0.0 1.7834 1.804 2.9009 
0.1 1.7783 1.799 2.8819 
0.2 1.7692 1.7898 2.8473 
0.3 1.7558 1.7763 2.797 
0.4 1.7383 1.7584 2.7309 
120 -0.4 1.1008 1.1091 1.5746 
-0.3 1.1081 1.1169 1.5982 
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-0.2 1.1128 1.122 1.6134 
-0.1 1.1149 1.1243 1.6201 
0.0 1.1144 1.124 1.6184 
0.1 1.1112 1.1209 1.6081 
0.2 1.1054 1.115 1.5894 
0.3 1.0969 1.1065 1.5622 
0.4 1.0858 1.0951 1.5265 
150 -0.4 0.8829 0.8879 1.2287 
-0.3 0.8888 0.8942 1.2469 
-0.2 0.8926 0.8983 1.2586 
-0.1 0.8943 0.9002 1.2638 
0.0 0.8939 0.8999 1.2624 
0.1 0.8914 0.8975 1.2545 
0.2 0.8867 0.8928 1.24 
0.3 0.8799 0.8859 1.219 
0.4 0.8709 0.8768 1.1915 
Table 25. MSE by correlation structure with misclassification of scenario 5 for responders. Proposed 
Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-weighted 
Bayesian model. 
 
Sample Size ρ Weighted VAR Adjusted Non-weighted 
75 -0.4 0.7449 0.7428 0.589 
-0.3 0.7422 0.7396 0.5801 
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-0.2 0.7406 0.738 0.5789 
-0.1 0.7385 0.736 0.5785 
0.0 0.7388 0.7358 0.5777 
0.1 0.7398 0.7356 0.58 
0.2 0.743 0.7389 0.5854 
0.3 0.7456 0.7404 0.5927 
0.4 0.7489 0.7447 0.6041 
120 -0.4 0.9114 0.9123 0.8075 
-0.3 0.9075 0.9094 0.7996 
-0.2 0.9071 0.9081 0.7951 
-0.1 0.9059 0.9076 0.7928 
0.0 0.9056 0.9081 0.7962 
0.1 0.907 0.9088 0.7991 
0.2 0.9094 0.9102 0.8025 
0.3 0.9123 0.9127 0.8094 
0.4 0.9162 0.9181 0.819 
150 -0.4 0.9622 0.964 0.8801 
-0.3 0.9607 0.9617 0.8755 
-0.2 0.9598 0.9606 0.8733 
-0.1 0.9596 0.9602 0.8728 
0.0 0.9596 0.9599 0.8718 
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0.1 0.9598 0.9607 0.8729 
0.2 0.9608 0.9617 0.877 
0.3 0.9623 0.9628 0.8807 
0.4 0.9649 0.9649 0.885 
Table 26. Power by correlation structure with misclassification of scenario 5 for responders. 
Proposed Bayesian weighted variance model; proposed Bayesian adjusted model; existing non-
weighted Bayesian model. 
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OpenBUGS Code 
##Model in Chapter 2 
model{ 
 for( i in 1 : n ) { 
##Stage I  
##Stage I likelihood, v0 baseline, v3 outcome of Stage I, T1 treatment assignment in 
##Stage I 
  y1[i] <- v3[i] - v0[i] 
  y1[i] ~ dnorm(mu1[i], tau1)   
  v0c[i] <- v0[i] - mean(v0[]) 
  mu1[i] <- alpha[1] + alpha[2] * v0c[i] + alpha[3] * T1[i]  
##Stage I treatment effect alpha[3] 
  I[i] <- step(0.5 - v3[i] / v0[i])                                               
  II[i] <- step(16 - v3[i]) 
  RR[i] <- step(I[i] + II[i] - 1) 
  R[i] <- equals(T1[i], 0) * (equals(RR[i], 0) + 1) + 1 
##RR[i] responder indicator with 0 non-responders, 1 responders  
##R[i] response-drug combination indicator with 1 drug-drug, 2 placebo responders, 3 
##placebo non-responders  
##Stage II 
##Stage II likelihood, v6 outcome of Stage II, T2 treatment assignment in Stage II 
  y2[i] <- v6[i] - v3[i] 
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  y2[i] ~ dnorm(mu2[i], tau2[R[i]]) 
  T[1 , i] <- 0 
  T[2 , i] <- T2[i] 
  T[3 , i] <- T2[i] 
  z1[i] <- v3[i] * equals(R[i], 1) 
  z2[i] <- v3[i] * equals(R[i], 2) 
  z3[i] <- v3[i] * equals(R[i], 3) 
  mu2[i] <- (beta1[1] + beta2[1] * T[1 , i] + gamma[1] * (v3[i] - 
mean(z1[]))) * equals(R[i], 1) + (beta1[2] + beta2[2] * T[2 , i] + gamma[2] * (v3[i] - 
mean(z2[]))) * equals(R[i], 2) + (beta1[3] + beta2[3] * T[3 , i] + gamma[3] * (v3[i] - 
mean(z3[]))) * equals(R[i], 3) 
##Model for missing covariates, included if there are missing covariates in the data 
v3[i] ~ dnorm(c1, d1) 
v6[i] ~ dnorm(c2, d2)            
 } 
##Stage II treatment effect for placebo non-responders beta2[3] 
##Priors 
 for( j in 1 : 3 ) { 
  alpha[j] ~ dnorm(0.0, 1.0E-3) 
  gamma[j] ~ dnorm(0.0, 1.0E-3) 
  beta1[j] ~ dnorm(0.0, 1.0E-3) 
  beta2[j] ~ dnorm(0.0, 1.0E-3) 
  tau2[j] ~ dgamma(0.001, 0.001) 
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 } 
 tau1 ~ dgamma(0.001, 0.001) 
 c1 ~ dnorm(0.0, 1.0E-3) 
c2 ~ dnorm(0.0, 1.0E-3) 
d1 ~ dgamma(0.001, 0.001) 
d2 ~ dgamma(0.001, 0.001) 
##overall weighted treatment effect delta  
 delta <- 0.64 * alpha[3] + 0.36 * beta2[3] 
 pw <- step( -delta) 
} 
##Model in Chapter 3, prior setting I, setting II and setting III 
model{ 
 for( i in 1 : n ) { 
##Stage I  
##Stage I likelihood, v0 baseline, v3 outcome of Stage I, T1 treatment assignment in 
##Stage I 
  y1[i] <- v3[i] - v0[i] 
  y1[i] ~ dnorm(mu1[i], tau1) 
  v0c[i] <- v0[i] - mean(v0[]) 
  mu1[i] <- alpha[1] + alpha[2] * v0c[i] + alpha[3] * T1[i] 
##Stage I treatment effect alpha[3] 
  I[i] <- step(0.5 - v3[i] / v0[i]) 
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  II[i] <- step(16 - v3[i]) 
  RR[i] <- step(I[i] + II[i] - 1) 
  R[i] <- equals(T1[i], 0) * (equals(RR[i], 0) + 1) + 1 
##RR[i] responder indicator with 0 non-responders, 1 responders  
##R[i] response-drug combination indicator with 1 drug-drug, 2 placebo responders, 3 
##placebo non-responders  
##Stage II 
##Stage II likelihood, v6 outcome of Stage II, T2 treatment assignment in Stage II 
  y2[i] <- v6[i] - v3[i] 
  y2[i] ~ dnorm(mu2[i], tau2[R[i]]) 
  T[1 , i] <- 0 
  T[2 , i] <- T2[i] 
  T[3 , i] <- T2[i] 
  z1[i] <- v3[i] * equals(R[i], 1) 
  z2[i] <- v3[i] * equals(R[i], 2) 
  z3[i] <- v3[i] * equals(R[i], 3) 
  mu2[i] <- (beta1[1] + beta2[1] * T[1 , i] + gamma[1] * (v3[i] - 
mean(z1[]))) * equals(R[i], 1) + (beta1[2] + beta2[2] * T[2 , i] + gamma[2] * (v3[i] - 
mean(z2[]))) * equals(R[i], 2) + (beta1[3] + beta2[3] * T[3 , i] + gamma[3] * (v3[i] - 
mean(z3[]))) * equals(R[i], 3) 
 } 
##Stage II treatment effect for placebo non-responders beta2[3] 
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##Priors, dependent prior setting beta2[3]=alpha[3]+zeta, zeta~exp 
 for( j in 1 : 3 ) { 
  alpha[j] ~ dnorm(0.0, 1.0E-3) 
  gamma[j] ~ dnorm(0.0, 1.0E-3) 
  beta1[j] ~ dnorm(0.0, 1.0E-3) 
  tau2[j] ~ dgamma(0.001, 0.001) 
 } 
 beta2[1] ~ dnorm(0.0, 1.0E-3) 
 beta2[2] ~ dnorm(0.0, 1.0E-3) 
##dependent prior setting I 
 beta2[3] <- alpha[3] + zeta 
 zeta ~ dexp(L) 
##dependent prior setting II 
##beta2[3] <- 2 * alpha[3] + alpha[3] * zeta 
##zeta ~ dnorm(0, 0.1) 
##dependent prior setting III 
##beta2[3] <- alpha[3] * k 
##k ~ dgamma(8, 5.556) 
 tau1 ~ dgamma(0.001, 0.001) 
 delta <- 0.64 * alpha[3] + 0.36 * beta2[3] 
##overall weighted treatment effect delta  
 pw <- step( -delta) 
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} 
##Model in Chapter 4, Bayesian Weighted Model 
model{ 
 for( i in 1 : n ) { 
##Stage I  
##Stage I likelihood, v0 baseline, v3 outcome of Stage I, T1 treatment assignment in 
##Stage I 
  y1[i] <- v3[i] - v0[i] 
  v0c[i] <- v0[i] - mean(v0[]) 
  y1[i] ~ dnorm(mu1[i], tau1) 
  mu1[i] <- alpha[1] + alpha[2] * v0c[i] + alpha[3] * T1[i] 
##Stage I treatment effect alpha[3] 
##Placebo non-response model   
  I[i] <- step(0.5 - v3[i] / v0[i]) 
  II[i] <- step(16 - v3[i]) 
  RR[i] <- step(I[i] + II[i] - 1) 
##RR[i] responder indicator with 0 non-responders, 1 responders  
  x[i] <- v3[i] / v0[i] – 1 
##Change from Baseline as predictor 
  RR[i] ~ dbern(p1[i]) 
  eta[i] <- theta[1] + theta[2] * v0[i] + theta[3] * x[i] + (theta[4] + theta[5] * 
v0[i] + theta[6] * x[i]) * T1[i] 
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  logit(p1[i]) <- max(min(eta[i], 5),  -5) 
  p1.cut[i] <- cut(p1[i]) 
##p1[i] use as weight 
  R[i] <- equals(T1[i], 0) + 1 
##R[i] = 2 Stage I placebo, Stage II randomized to P and D, R[i] =1 Drug 
  g[i] <- equals(R[i], 1) * 1 + equals(R[i], 2) * p1.cut[i] 
##Stage II 
##Stage II likelihood, v6 outcome of Stage II, T2 treatment assignment in Stage II, 
##incorporating Placebo non-response in the model 
  y2[i] <- v6[i] - v3[i] 
  tau22[i] <- tau2[R[i]] / g[i] 
  T[1 , i] <- 0 
  T[2 , i] <- T2[i] 
  v3c[i] <- v3[i] - mean(v3[]) 
  y2[i] ~ dnorm(mu2[i], tau22[i]) 
  mu2[i] <- (beta1[1] + beta2[1] * T[1 , i] + gamma[1] * v3c[i]) * 
equals(R[i], 1) + (beta1[2] + beta2[2] * T[2 , i] + gamma[2] * v3c[i]) * equals(R[i], 2) 
 } 
##Stage II treatment effect for placebo non-responders beta2[2] 
##priors 
 for( k in 1 : 3 ) { 
  alpha[k] ~ dnorm(0.0, 0.01) 
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 } 
 for( j in 1 : 2 ) { 
  gamma[j] ~ dnorm(0.0, 0.01) 
  beta1[j] ~ dnorm(0.0, 0.01) 
  beta2[j] ~ dnorm(0.0, 0.01) 
  tau2[j] ~ dgamma(0.001, 0.001) 
 } 
 theta[1] ~ dnorm(0.0, 10) 
 theta[2] ~ dnorm(0.0, 10) 
 theta[3] ~ dnorm(0.0, 10) 
 theta[4] ~ dnorm(0.0, 0.01) 
 theta[5] ~ dnorm(0.0, 0.01) 
 theta[6] ~ dnorm(0.0, 0.01) 
 tau1 ~ dgamma(0.001, 0.001) 
##overall treatment effect  
 delta <- 0.64 * alpha[3] + 0.36 * beta2[2] 
 pw <- step( -delta) 
 delta1 <- 0.5 * alpha[3] + 0.5 * beta2[2] 
 pw1 <- step( -delta1) 
} 
##Model in Chapter 4, Bayesian Adjusted Model 
model{ 
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 for( i in 1 : n ) { 
##Stage I  
##Stage I likelihood, v0 baseline, v3 outcome of Stage I, T1 treatment assignment in 
##Stage I 
  y1[i] <- v3[i] - v0[i] 
  v0c[i] <- v0[i] - mean(v0[]) 
  y1[i] ~ dnorm(mu1[i], tau1) 
  mu1[i] <- alpha[1] + alpha[2] * v0c[i] + alpha[3] * T1[i] 
##Stage I treatment effect alpha[3] 
##Placebo non-response model 
  I[i] <- step(0.5 - v3[i] / v0[i]) 
  II[i] <- step(16 - v3[i]) 
  RR[i] <- step(I[i] + II[i] - 1) 
##RR[i] responder indicator with 0 non-responders, 1 responders  
  x[i] <- v3[i] / v0[i] – 1 
##Change from Baseline as predictor 
  RR[i] ~ dbern(p1[i]) 
  eta[i] <- theta[1] + theta[2] * v0[i] + theta[3] * x[i] + (theta[4] + theta[5] * 
v0[i] + theta[6] * x[i]) * T1[i] 
  logit(p1[i]) <- max(min(eta[i], 5),  -5) 
  p1.cut[i] <- cut(p1[i]) 
##p1[i] use as covariate 
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##R[i] = 2 Stage I placebo, Stage II randomized to P and D, R[i] =1 Drug 
  R[i] <- equals(T1[i], 0) + 1 
  f[i] <- equals(R[i], 1) * 0 + equals(R[i], 2) * p1.cut[i] 
##Stage II 
##Stage II likelihood, v6 outcome of Stage II, T2 treatment assignment in Stage II, 
##incorporating Placebo non-response in the model 
  y2[i] <- v6[i] - v3[i] 
  T[1 , i] <- 0 
  T[2 , i] <- T2[i] 
  v3c[i] <- v3[i] - mean(v3[]) 
  y2[i] ~ dnorm(mu2[i], tau22[R[i]]) 
  mu2[i] <- (beta1[1] + beta2[1] * T[1 , i] + gamma[1] * v3c[i] + kk[1] * 
f[i]) * equals(R[i], 1) + (beta1[2] + beta2[2] * T[2 , i] + gamma[2] * v3c[i] + kk[2] * f[i]) 
* equals(R[i], 2) 
 } 
##Stage II treatment effect for placebo non-responders beta2[2] 
##priors 
 for( k in 1 : 3 ) { 
  alpha[k] ~ dnorm(0.0, 0.01) 
 } 
 for( j in 1 : 2 ) { 
  gamma[j] ~ dnorm(0.0, 0.01) 
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  beta1[j] ~ dnorm(0.0, 0.01) 
  beta2[j] ~ dnorm(0.0, 0.01) 
  tau22[j] ~ dgamma(0.001, 0.001) 
  kk[j] ~ dnorm(0.0, 0.01) 
 } 
 theta[1] ~ dnorm(0.0, 10) 
 theta[2] ~ dnorm(0.0, 10) 
 theta[3] ~ dnorm(0.0, 10) 
 theta[4] ~ dnorm(0.0, 0.01) 
 theta[5] ~ dnorm(0.0, 0.01) 
 theta[6] ~ dnorm(0.0, 0.01) 
 tau1 ~ dgamma(0.001, 0.001) 
 delta <- 0.64 * alpha[3] + 0.36 * beta2[2] 
 pw <- step( -delta) 
 delta1 <- 0.5 * alpha[3] + 0.5 * beta2[2] 
 pw1 <- step( -delta1) 
} 
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